CLOSE ×

 

 

Cell Line References

Tissue sub-type Cell line References Mice Models Rats Hamsters
Cancer Stem Cells (Human Tissue)
Breast E1KD-GFP 486 NOD.SCID
Adenocarcinoma H1975 535, 856 B-NDG, nude
Glioma OCT4/SOX2 462 SCID-beige
Brain U87-SC 232 nude
Breast (mammary) LTR-MycER DCIS 482 NOD-SCID
Breast MCF-7 (mammospheres) 235 nude
Breast BCM-2147 340, 577 SCID-beige
Brain Glioblastoma 331, 341, 343, 432 NOD.SCID, nude
Lung H1299 108, 573, 711, 790 nude, B-NDG
Breast NMuMG-RFP 486 NOD.SCID
Brain BTSC83 200 nude
Breast BCM-3887 340 SCID-beige
Breast BCM-4195 340 SCID-beige
Gastric GSC1 471 SCID-beige
Breast MCF-7 (CSC-like) 236, 708 nude nude
Brain LA-N-5 231 nude
Brain NGC-407-GFP 206 nude
Breast BCM-2665 340 SCID-beige
Ovarian SKOV-3 (spherical cells) 213 BALB/c nude
Ovarian A2780-CR5 [ALDH(+) and ALDH(-)] 350 nude
Colon Colon tumor tissue 428 NOD.SCID
Breast 2LMP (MDA-MB-231 subclone) 234 NOD.SCID
Breast SUM159 234, 629, 711, 897, 917 NOD.SCID, nude
Lung A549 108, 501, 573 nude
Adenocarcinoma A549 535 B-NDG
Glioma CD133 462 SCID-beige
Prostate DU-145 (spheroid cells) 233 NOD.SCID
Human Tissue
Breast MCFDCIS 518 nude
Bronchial HBEC-3KT/KP 894 NOD.SCID
Colon SW48PK 695 R2G2
Breast MCF-7FGFR1 515 nude
Cervical Hep-2 (HeLa contaminant) 345 BALB/c nude
Colorectal DLD-1-HDAC2 KO-shH19 651 B-NDG
Breast MDA-MB-231-DR5-3RE 840 nude
Breast MDA-MB-231-MSLN 797 B-NDG
Esophageal OE47 154 nude
Colon Colo205 180, 299, 719 nude, NOD.SCID, C.B-17 SCID nude
Breast MDA-MB-435 12 nude
Breast MDA-MB-231-DR5-KO 840 nude
Breast MDA-MB-231-shYBX1 616 nude
Colorectal DLD-1-HDAC2 KO-shH19 651 B-NDG
Carcinoma HCC95 517 nude
Breast JIMT-1 68, 69, 226, 289 C.B-17 SCID, NMRI nude, nude, SCID
Colorectal CX-1 20 nude
Gastric N87 70, 143, 164, 175, 258, 461, 619, 822 NMRI nude, nude, SCID, SCID-beige
Endometrial Ishikawa 716, 907 C.B-17 SCID
Esophageal OE21 154 nude
Breast MCF/HER2-18 160 nude
Breast MDA-MB-231-PEA15 816 nude
Colon LS411N 392 nude
Leukemia MV4-11 166, 179, 180, 181, 182, 296, 348, 791 NOD.SCID, nude, B-NDG nude
Glioblastoma CHLA-200 598 nude
Lung A549-Red-FLuc Bioware® Brite Cell Line 585, 819 nude
Head & Neck Squamous Cell Carcinoma (HNSCC) WSUHN-31 60 nude
Leukemia HMC1.1 688 SCID-beige
Lung L2987 143 SCID-beige, nude
Head & Neck Squamous Cell Carcinoma (HNSCC) Cal-27 65, 66, 67 nude
Lung NCI-H520 694 R2G2, Nude
Melanoma A375M 249 nude
Melanoma NIH1286 84 nude
Mesothelioma shNT HCT116 525 nude
Lymphoma OCI-Ly8 783 B-NDG
Multiple Myeloma MM.1S-GFP 686 SCID-beige
Melanoma A375 163, 281, 306, 316, 955 nude
Lung NCI-H841 354 SHrN®
Lymphoma SP53 30 SCID
Lung NCI-H1650 795 B-NDG
Lymphoma (PCNSL-primary CNS lymphona) PCNSL-10 615 nude
Lymphoma SU-DHL-2 538 B-NDG
Lung TC1 Luc 519 nude
Lung NCI-H661 694 R2G2, Nude
Multiple Myeloma MM.1S PTX 738 SCID-beige
Melanoma SK-MEL31-VEGFR2R1051Q 754 NOD.SCID
Lymphoma (PCNSL-primary CNS lymphona) PCNSL-14 615 nude
Prostate LAPC4 107, 352 nude
Melanoma SIT1 37 SCID
Multiple Myeloma ARD 796 B-NDG
Ovarian HEY 269 nude
Pancreatic Bx/shRON 276 nude
Pancreatic BxPC-3 42, 275, 276, 572, 852 nude
Prostate LNCaP-iMAPK4 741 SCID-beige
Ovarian OVCAR4 522 nude
Ovarian OVCAR8 458 SCID-beige
Ovarian A2780 434, 985 C.B-17 SCID
Prostate PC-3-RFP 872 nude
Pancreatic MIA-Luc 202 nude
Multiple Myeloma NEK2‐OE KMS11 537, 670 B‐NDG, NOD.SCID
Pancreatic CFPAC-1 394 nude
Ovarian 1A9ptx10 78 nude
Pancreatic Colo357 42, 44, 251, 736 nude, SCID-beige
Pancreatic 96 709 nude
Prostate CWR22-HOXB13ko 623 nude
Prostate LuCaP35 916 CB.17-SCID
Prostate CWR22-HOXB13ko 623 nude
Prostate CWR22-MEIS1 623 nude
Pancreatic S2CP9 655 C.B-17 SCID
Pancreatic PL45 43, 870 nude
Pancreatic L3.6pl 123, 236 nude
Prostate LuCap167 812 nude
Prostatic Adenocarcinoma LAPC4 909 nude
Multiple Myeloma U266 242, 489 NOD.SCID
Ovarian CD228 143 nude, SCID-beige
Prostate PAC120 594 nude
Teratoma multipotent mesenchymal stromal cells (MSC) 674 NOD.SCID
Renal SMMC-7721-luciferase 534 B-NDG
Sarcoma (Malignant peripheral nerve sheath tumors ) STS-26T 823 nude
Renal C3H10T1/2 794 B-NDG
Renal ACHN 328 NOD.SCID
Renal Caki-1 444, 605, 810 nude
Thyroid H157 464 SCID-beige
Uveal melanoma OCM1a 102 SCID
Gastric RN-87 461 SCID-beige
Head & Neck Squamous Cell Carcinoma (HNSCC) UMSCC38 279 nude
Brain primary glioblastoma cells 832 nude
Bladder KU-7 148, 149, 150, 151 nude
Bladder T24 52, 478, 591 NOD.SCID, nude nude
Brain TB10 200 nude
Adenocarcinoma H1373 902 nude
Bladder H157 464 SCID-beige
Brain GS-11 397 SHrN®
Breast GPX4 iKO BT474 562 nude
Brain HTB-14IG 920 nude
Breast BT474-EEI 252, 556 beige-nude-xid
Brain (diffuse intrinsic pontine glioma) TT150728 546 B-NDG
Brain U251 81, 202, 414, 422, 427, 817, 918 nude nude
Brain D425 Med 524 nude
Brain U87-TARTK 208 NOD.SCID
Brain T98G 910 nude
Bladder H1299 464 SCID-beige
Brain WAC2 443 nude
Bladder RT4 478 NOD.SCID
Brain U87 71, 81, 117, 173, 196, 414, 450, 529, 566, 615, 680, 705, 743, 817, 901, 965 NMRI nude, nude, SCID, SCID-beige nude, RAG2 KO(SD)
Brain U87MG 4, 78, 80, 83, 133, 134, 164, 195, 198, 201, 205, 206, 209, 224, 249, 342, 404, 427, 550, 596, 825, 827, 839, 903 BALB/c SCID, beige-nude-xid, CD-1 nude, NMRI nude, nude, SCID, B-NDG nude
Bladder HT-1376 478 NOD.SCID
Brain G55 3, 445, 846, 941, 953 nude nude
Breast Gem197 726 CB.17-SCID, nude
Adrenal H295R 584 nude
Brain U138MG 203, 266 NOD.SCID, nude
Breast MDA-MB-231-5T4OE 850 nude
Breast BT-474/TR 161, 162 nude
Brain HTLA-230 5, 125 SCID-beige, nude
Brain U251-NG2 1, 285 nude
Brain D384 Med 524 nude
Breast CACNA1H 500 NOD.SCID
Gastric SNU-216 461 SCID-beige
Head & Neck Squamous Cell Carcinoma (HNSCC) FaDu 21, 65, 244, 555, 582, 813, 824, 976 nude nude
Head & Neck Squamous Cell Carcinoma (HNSCC) SCC1 (cetuximab-resistant) 395 nude
Leukemia (acute myeloid) AML 466 SCID-beige
Lung Calu6 142, 143, 299, 604 NOD.SCID, SCID-beige, nude nude
Lung A549m 279 nude
Head & Neck Squamous Cell Carcinoma (HNSCC) CCL 23 (HeLa contaminant) 67 nude
Head & Neck Squamous Cell Carcinoma (HNSCC) UMSCC104 815 nude
Leukemia K562 171, 396, 545, 911 C.B-17 SCID, SHrN®, B-NDG
Leukemia KBM5T315I 785 B-NDG
Leukemia GFP‐labeled Reh PRPS1 547 B-NDG
Liver Huh-7 122, 779 SCID, B-NDG
Breast ZR-75-1 299, 429, 706, 708 nude, NOD.SCID nude
Breast MDA-MB-231-469 818 nude
Breast T47D 6, 7, 130, 210, 229, 259, 310, 313, 402 BALB/c nude, nude, SCID-beige
Colorectal HCT-116 17, 18, 19, 112, 143, 153, 164, 413, 419, 564, 604, 886, 935 nude, SCID, SCID-beige, B-DNG
Breast MDA‐231 LeptoM 942 nude
Breast MDA-MB-361 60, 256, 313, 826 nude
Glioblastoma L0306 758 NOD.SCID
Glioma DIPG007 633, 922 nude
Head & Neck, Breast PDX 567 nude
Lung H226B 279 nude
Glioblastoma P13 596 nude
Lung A549-luc 587, 645, 900 nude, NOD.CB17-Prkdcscid IL2rgtm1/BcgenHsd
Liver KFJ9 307 SCID-beige
Head & Neck Squamous Cell Carcinoma (HNSCC) SE-Pt#5 479 NOD.SCID
Lung A549 9, 11, 15, 33, 109, 110, 117, 122, 143, 183, 244, 258, 416, 472, 492, 514, 691, 710, 819, 842, 843, 853 NMRI nude, nude, SCID, SCID-beige, NOD.SCID nude
Lung NCI-H1229 776 B-NDG
Lymphoma TMD8 751, 892 NOD.SCID
Mesothelioma hMerlin-Gpx4 iKO-TGL MSTO-211H 487 NOD-SCID
Melanoma Ge 248 SCID-beige
Melanoma VM 317 BALB/c SCID
Multiple Myeloma MM.1S-Luc 656 C.B-17 SCID
Mesothelioma shLats1/2 HCT116 525 nude
Lymphoma Human Lymphoma B (P493) 453 CB-17
Lymphoma GA10 854 nude
Melanoma Primary melanoma cells 957 nude
Multiple Myeloma RPMI-8226 489, 669, 670, 760 NOD.SCID
Pancreatic PANC-1 42, 167, 168, 491 ,597, 709, 803 nude, NOD.SCID, B-NDG
Ovarian fLuc+ SK-OV-3 539 B-NDG
Prostate 22Rv1 513, 583, 697, 714, 731 nude, R2G2, C.B-17 SCID, SCID-beige
Prostate LuCaP49 916 CB.17-SCID
Pancreatic HPAC 299 nude nude
Ovarian MW387 143 nude, SCID-beige
Ovarian 1A9 78 nude
Pancreatic Panc185 272 nude
Prostate PC3 560, 711, 717, 841 nude, C.B-17 SCID
Prostate PC-3 46, 47, 48, 49, 129, 135, 138, 143, 169, 209, 211, 216, 220, 240, 246, 283, 302, 513, 562, 594, 596, 722, 755, 756, 812, 905 BALB/c nude, BALB/c SCID, beige-nude-xid, MF1 nude, nude, SCID, SCID-beige, NOD.SCID
Osteosarcoma 143B 405, 433, 958 C.B-17 SCID
Neuroblastoma SK-N-BE(2) 600, 763 nude
Multiple Myeloma RPMI 303, 304, 305 C.B-17 SCID, SCID
Multiple Myeloma ARP-1 144, 723, 782, 784 SCID, CB.17-SCID, B-NDG
Lymphoma (PCNSL-primary CNS lymphona) PCNSL-5 615 nude
Renal 786O 127, 138, 180, 654, 718, 794 BALB/c nude, MF1 nude, NOD.SCID, nude, C.B-17 SCID, B-NDG
Skin (Merkel Cell Carcinoma) MCPyV-positive MCC cell lines 483 NOD.SCID
Colon MV522 180 nude, NOD.SCID
Bladder H157 464 SCID-beige
Brain A-172 198 nude
Brain U251 MG 198, 199, 550 nude, B-NDG
Bladder J82-Ras 591 nude
Breast HCC1569 162 nude
Breast HCC-1806 948 nude
Brain SH-SY5Y 2, 563, 887 nude nude
Breast Gem257 726 CB.17-SCID, nude
Breast Gem240 726 CB.17-SCID, nude
Brain T87 GSC 400, 425 nude
Brain U87Fluc 79, 82 BALB/c nude, nude
Bladder T24- Luc 531 B-NDG
Gastric NUGC-3 719 C.B-17 SCID
Gastric ROE-19 461 SCID-beige
Gastric SNU16 719 C.B-17 SCID
Head & Neck Squamous Cell Carcinoma (HNSCC) SCC1483 395 nude
Head & Neck Squamous Cell Carcinoma (HNSCC) CCL-138 947 nude
Head & Neck Squamous Cell Carcinoma (HNSCC) Cal33 555 nude
Leukemia HMC1.2 688 SCID-beige
Glioma BT3 622 nude
Head & Neck Squamous Cell Carcinoma (HNSCC) UM-SCC1 66, 67, 116, 284 nude
Liver HuCCT1 262 nude
Lung H1299 464 SCID-beige
Lung NCI-H1229-PD1 776 B-NDG
Lung H292 407 nude
Gastrointestinal GIST-T1 436 SCID-beige
Leukemia THP-1 75 C.B-17 SCID
Lung LX-1 143 SCID-beige, nude
Glioma HSJD-DIPG-007 633 nude
Glioblastoma P3-stem cell-like 596 nude
Liver Hep-G2 122, 548, 788, 960 SCID, B-NDG
Leukemia RPMI 8666 688 SCID-beige
Liver AKH10 307 SCID-beige
Head & Neck Squamous Cell Carcinoma (HNSCC) HeLa-O3 330 nude
Head & Neck Squamous Cell Carcinoma (HNSCC) HNX-OE 21 nude
Lung KNS-62 34, 88, 89 SCID-beige
Glioblastoma SJGBM2-Ctr, SJGBM2-ΔNp73 598 nude
Leukemia NALM6 ALL 549 B-NDG
Head & Neck Squamous Cell Carcinoma (HNSCC) HN-31 947 nude
Lung Colo-699 34, 88, 89 SCID-beige
Glioblastoma G9pCDH-copGFP 590 nude
Liver SMMC-7721 778 B-NDG
Liver Hep3B 25, 101, 119, 137, 222, 223, 225, 392 nude nude
Liver KFJ10 307 SCID-beige
Lung H358 31, 595, 982 nude
Hematopoetic iTregs 647 B-NDG
Head & Neck Squamous Cell Carcinoma (HNSCC) SE-Pt#6 479 NOD.SCID
Lung H865 409 nude
Bladder UM-UC1 278 nude
Brain D341 Med 524 nude
Bladder UM-UC13 278 nude
Bladder 5637 478 NOD.SCID
Breast 231/LM2-4 353 nude
Brain IMR32 568, 944 nude
Cervical HeLa 78, 124, 344, 346, 347, 449, 706, 981 nude nude
Breast SK-BR3 630, 665, 951 nude, C.B-17 SCID
Breast KPL-4 143, 627, 667, 749 nude, SCID-beige, NOD.SCID
Gastric mABL001 719 C.B-17 SCID
Breast MDA-MB-231-shFBXO44 611 nude
Esophageal OE19 126, 127, 138, 154, 175 BALB/c nude, MF1 nude, nude, SCID
Colon SW403 392 nude
Esophageal OE33 154, 155, 172 nude
Colon HCA-7 17 nude
Breast MDA-MB-231-Luc 477, 575, 611, 837, 867 NOD.SCID, nude
Breast MDA-MB-231 9, 11, 12, 15, 56, 71, 94, 111, 116, 136, 139, 143, 156, 174, 176, 177, 184, 185, 186, 187, 188, 189, 190, 191, 193, 209, 217, 267, 287, 299, 354, 408, 431, 442, 454, 481, 504, 510, 516, 624, 625, 678, 693, 708, 757, 767, 811, 816, 826, 833, 844, 848, 869, 877, 883, 888, 904, 946, 967, 972 BALB/c SCID, CD-1 nude, nude, NOD.SCID, SCID, SCID-beige, CB-17 nude
Gastric OE-19 461 SCID-beige
Brain U251-lucRFP 884 nude
Breast MEF-p95-HER2 64 nude
Colon Colo320 113 nude
Colon SW480 122 SCID
Breast MCF-7eGFP 515 nude
Breast USC ARK-2 cells 712 C.B-17 SCID
Breast MDA-IBC3 401, 731, 742, 745, 746, 896 SCID-beige
Breast shOBR MDA-MB-231 579 nude
Colon KM-12 606 nude
Colon HCT-15 338 nude
Breast HCC70 734, 963 SCID-beige
Breast MCF-7 8, 14, 24, 97, 103, 128, 130, 131, 132, 138, 143, 146, 192, 210, 217, 218, 219, 226, 229, 230, 255, 256, 290, 308, 309, 310, 311, 312, 313, 354, 412, 468, 608, 629, 739, 826, 834, 851, 864, 948, 959 BALB/c nude, CD-1 nude, MF1 nude, nude, SCID, SCID-beige, SHrN® nude
Cervical ME-180 291 nude
Breast MCF-7FGFR1(SP-)(NLS) 851 nude
Breast MDA-MB-231-mCherry 282 nude
Colorectal SW620 243, 294, 578, 787, 849, 876, 956 nude, B-NDG
Gastric HS746T 417 nude
Colorectal HT-29 16, 22, 23, 114, 115, 116, 117, 141, 143, 147, 239, 263, 295, 299, 347, 564, 571 BALB/c nude, beige-nude-xid, NMRI nude, nude, SCID-beige nude
Breast MCF-GFP 349 nude
Breast MDA-MB-231-DR5-3RA 840 nude
Leukemia (acute myeloid) RUVBL1/2 465 SCID-beige
Kidney HEK-SST5 618, 621 nude
Skin (benign) Shope papilloma 301 nude
Vulva SK-LMS-1 145 nude
Testicular NCCIT 53 nude
Thyroid CAL62 496 NOD.SCID
Thyroid CAL62-splice cells 496 NOD.SCID
Uterine serous carcinoma CCL-155 664 C.B-17 SCID
Sarcoma (Malignant peripheral nerve sheath tumors ) ST88-14 823 nude
Lymphoma (PCNSL-primary CNS lymphona) PCNSL-16 615 nude
Melanoma SK-MEL23 323 beige-nude-xid
Lymphoma Nalm6 472 SCID-beige
Lymphoma (Plasmacytoma) CCL-155 727 C.B-17 SCID
Melanoma DM6 85 nude
Lymphoma Z138 238 SCID
Multiple Myeloma MM.1S 120, 144, 399, 489, 493, 747, 789 C.B-17 SCID, SCID, NOD.SCID, B-NDG
Lung NCI-H69 143, 354, 615 nude, SCID-beige, SHrN®
Lymphoma Ly10 724 C.B-17 SCID
Melanoma MeWo 943 nude
Lymphoma (PCNSL-primary CNS lymphona) PCNSL-11 615 nude
Lung PC9 LeptoM 942 nude
Pancreatic Panc354 614 nude
Ovarian OV8-mcherry 612 nude
Neuroblastoma COA3 484, 565, 763, 838, 898 NOD.SCID, nude
Lymphoma L540cy 28 SCID
Ovarian SARARK9 661 C.B-17 SCID
Melanoma 607B 247 SCID
Lung NCI-H460 114, 225, 293, 297, 964 C.B-17 SCID, nude nude
Mesothelioma DEVy 100 nude
Osteosarcoma OS-17 433, 866 C.B-17 SCID, nude
Lymphoma HBL-1 720, 724 C.B-17 SCID
Melanoma MelM9 322 C.B-17 SCID
Lymphoma Karpas-299 28, 90, 542, 654, 718 SCID, B-NDG, C.B-17 SCID
Lymphoma (PCNSL-primary CNS lymphona) PCNSL-14 615 nude
Lymphoma SUP-T1-luc 576 nude
Lung NCI-H292 777, 781 B-NDG
Multiple Myeloma KMS11-PTX 752 NOD.SCID
Mesothelioma shNT-Gpx4 iKO-TGL MSTO-211H 487 NOD.SCID
Melanoma FM82 320 NOD.SCID
Lymphoma (PCNSL-primary CNS lymphona) PCNSL-6 615 nude
Prostate LNCaP-HSD17B2 541 B-NDG
Ovarian NMP-1 96 nude
Prostate CWR22 51, 143, 623, 713 nude, SCID-beige, C.B-17 SCID
Lymphoma Granta 519 30, 144 SCID
Melanoma C8161.9 744 SCID-beige
Pancreatic Panc89 45 SCID
Pancreatic Capan-2 709 nude
Prostate CDX 594 nude
Pancreatic BxPC3/shSTAT3 280 nude
Ovarian PEO4ip 740 SCID-beige
Ovarian OV90-KRCCshRNA, OC90-ctrl 603 nude
Pancreatic S2VP10 655 C.B-17 SCID
Ovarian SKOV3-luc 237, 446, 632, 642 nude, B-NDG nude
Oral KB (HeLa contaminant) 299 nude nude
Renal Primary (Immortalized) 439 SCID-beige
Ovarian ES2 580 nude
Leukemia HPB-ALL 27 nude
Kidney HEK-SST2 618, 621, 830 nude
Leukemia (acute myeloid) AML1-ETO 512 nude
Lung BEN 88 SCID-beige
Glioblastoma P22 596 nude
Lung A549shHTATIP2 586 nude
Head & Neck Squamous Cell Carcinoma (HNSCC) SE-Pt#1 479 NOD.SCID
Liver KFJ6 307 SCID-beige
Leukemia ARH-77 298 C.B-17 SCID
Leukemia Reh ALL 549 B-NDG
Head & Neck Squamous Cell Carcinoma (HNSCC) SCC-1 284 nude
Leukemia KG-1 144 C.B-17 SCID
Head & Neck Squamous Cell Carcinoma (HNSCC) SE-Pt#3 479 NOD.SCID
Head & Neck Squamous Cell Carcinoma (HNSCC) SE-Pt#2 479 NOD.SCID
Leukemia MEC-2 677 R2G2®
Leukemia HEL9217 57 C.B-17 SCID
Liver HuH7 728, 969 C.B-17 SCID
Lung 95D 800 B-NDG
Kidney HEK293T (ACE2 Expressing) 973 nude
Glioblastoma NCH421K 596 nude
Leukemia HL60 57, 171 C.B-17 SCID
Lung Calu-1 694 R2G2, Nude
Glioblastoma SJGBM2-luc 598 nude
Leukemia ERY-1 502 nude
Glioblastoma DBTRG-shCtr, DBTRG-shΔNp73 598 nude
Lung H226 (NSCLC) 395 nude
Liver HuH6 26, 411, 415, 506, 762, 940 nude, NOD.SCID nude
Liver HepT1 25 nude
Head & Neck Squamous Cell Carcinoma (HNSCC) SE-Pt#4 479 NOD.SCID
Leukemia TF1-α 57 C.B-17 SCID
Brain GL15 286 C.B-17 SCID
Brain U87ΔEGFR 197 nude mice
Breast AU565 581 nude
Brain (astrocytoma) U87 528 RAG2 KO(SD)
Brain SH-EP 443 nude
Brain HTB-14 920 nude
Brain U87MG.wt EGFR 203 nude mice
Bladder UM-UC3 871 nude
Breast BICR6 734 SCID-beige
Breast BT-474/AZ 863 nude
Breast BT-474 61, 62, 72, 143, 157, 160, 161, 162,163, 165, 211, 227, 228, 258, 270, 601 BALB/c nude, nude, C.B-17 SCID, SCID-beige
Brain U373 207 nude
Breast Gem256 726 CB.17-SCID, nude
Bladder 5637-Luc 551 B-NDG
Brain (Medulloblastoma) G3 MB Med-411FHTC 861 nude
Breast BT-474-M1 178, 253, 254, 257, 288 beige-nude-xid, nude, SCID
Breast BT549 442, 797 nude, B-NDG
Brain (diffuse intrinsic pontine glioma) TT150630 546 B-NDG
Breast BT-474R2 527 nude
Breast BT-474C 299 nude nude
Breast Gem270 726 CB.17-SCID, nude
Brain U87-CXCR4 615 nude
Breast DCIS.com lifeact-RFP 893 NOD.SCID
Breast MDA-MB-468 226, 260, 266, 421, 581, 667 nude, NOD.SCID, SCID
Breast MDA-MB-231-GFP 617 nude
Colon Widr 719 C.B-17 SCID
Carcinoma Sk-HEP-1 (nano-Luc+) 553 B-NDG
Gastric MKN45 124, 719 nude, C.B-17 SCID
Esophageal FLO-1 172, 559 nude
Breast MDA-MB-231-LM2 726 CB.17-SCID, nude
Breast MDA-MB-453 158, 256 nude
Breast MT-1 13, 170, 245 CD-1 nude, nude nude
Breast (mammary) HME-Gem9 726 C.B-17 SCID
Colon SW48 509, 604, 695, 719 nude, R2G2, C.B-17 SCID
Endometrial ECC-1 312 nude
Breast shOBR-MCF-7 579 nude
Colon Colo201 338 nude
Colorectal DLD-1-HDAC2 KO 651 B-NDG
Breast MIV-shSCR 480 NOD.SCID
Colon LS174T 63, 140, 159, 392 nude
Colon LIM1215 509 nude
Breast SUM149 401 SCID-beige
Carcinoma CMV-luciferase 552 B-NDG
Gastric HGC27 961 nude
Breast MCF-RSK4 349 nude
Colon BCS-TC2.2 113 nude
Fibrosarcoma HT1080 77, 124, 209, 406, 607 BALB/c SCID, nude
Breast MIV-INHBA 480 NOD.SCID
Colorectal DLD-1 16, 152, 243, 294, 651 nude, B-NDG
Breast T47D-TAMR 868 nude
Gastric JIMT-1 461 SCID-beige
Colon Colo320-CD9 113 nude
Gastric AGS 978 Balb/c nude
Colon GEO 143, 258, 338 nude, SCID-beige
Colon Carcinoma RKO 962 BALB/c nude
Cervical SiHa 291, 588, 802 B-NDG nude
Colon LoVo 116, 299, 956 nude nude
Colorectal HCT-116-luc 780 B-NDG
Carcinoma KYSE-180 517 nude
Breast MDA-MB-175 253 beige-nude-xid
Colon HCT116 858, 906 nude
Lung H2122 507, 982 nude
Liver COA67 506, 762 nude, NOD.SCID
Squamous Cell Carcinoma SiHa (miR‐200a/b/‐429‐overexpressing) 945 nude
Retinoblastoma Y79 241 nude
Thyroid H1299 464 SCID-beige
Thyroid THJ‐16T 676 R2G2®
Uveal melanoma M619 102 SCID
Sarcoma (Malignant peripheral nerve sheath tumors ) S462-TY 823 nude
Renal G401 415 nude
Renal Caki-2 329 nude
Squamous-cell/epidermoid carcinoma A431 143, 211, 262, 264, 265, 266, 267, 268, 412, 850 NOD.SCID, nude, SCID-beige
Renal Caki-1-MCPIP1 810 nude
Uveal melanoma OMM2.5 908 nude
Renal MRKT 415 nude
Renal Caki-1 CLDN7-Luc 533 B-NDG
Renal SK-NEP-1 415 nude
Vulva A431 327, 345 BALB/c nude, NOD.SCID
Thyroid BHT101 860, 890 nude
Tongue CAL27 986 BALB/c nude
Uterine serous carcinoma ARK2 663 C.B-17 SCID
Uveal melanoma MUM2B 102 SCID
Skin (HPV16)BC-1-Ep/SL-LF 314 beige-nude-xid, nude, SHrN®
Lung NCI-H82 118, 615, 694 nude, R2G2
Multiple Myeloma KMS11 748 NOD.SCID
Lung Cancer HCC827 HCC827-ER1 570 nude
Lung NCI-H441 643 B-NDG
Lung adenocarcinoma H1299 464 SCID-beige
Lymphoma Raji 542, 543, 643, 646, 698 B-NDG, R2G2
Multiple Myeloma L-363 120 SCID
Melanoma 537MEL 323 beige-nude-xid
Melanoma SK-MEL30 604 nude
Lymphoma (AML) MOLM-13 707 nude
Lymphoma REC-1 520, 724 nude, CB.17-SCID
Lung adenocarcinoma H157 464 SCID-beige
Lymphoma (PCNSL-primary CNS lymphona) PCNSL-15 615 nude
Multiple Myeloma KAS-6/1 76 SCID
Melanoma 518A2 122, 247, 319, 321 C.B-17 SCID, SCID
Lymphoma OCI-Ly8-PDK4 783 B-NDG
Melanoma A2058 318 SCID
Multiple Myeloma NCI-H929 242 NOD.SCID
Multiple Myeloma AMO-1 489 NOD.SCID
Melanoma SK-MEL31 754 NOD.SCID
Melanoma UACC 315, 903 nude
Lung PC9 733, 795, 856, 900 SCID-beige, B-NDG
Melanoma Mel-JUSO 247 SCID
Lymphoma Daudi 701, 702, 724 B-NDG hIL15, SCID
Multiple Myeloma LAGΛ-1 74, 75 nude
Multiple Myeloma MPC-11 325 beige-nude-xid
Pancreatic Panc430 262 nude
Ovarian PDX 574, 672, 684 nude
Prostate VCaP 215, 513 nude
Multiple Myeloma RUVBL1/2 465, 508 SCID-beige, nude
Ovarian KRCH31 660 C.B-17 SCID
Prostate ARCaPM 521 nude
Ovarian A2780 143, 350 nude, SCID-beige
Prostate LuCap 23.1 865 nude
Prostate 22Rv1-ishMAPK4 741 SCID-beige
Pancreatic PSN1 987 BALB/c nude
Ovarian SKOV-3 38, 40, 41, 55, 86, 92, 93, 95, 211, 212, 213, 214, 292, 324, 722, 781 BALB/c nude, beige-nude-xid, nude, SCID, NOD.SCID, CB.17-SCID B-NDG nude
Multiple Myeloma U266-GFP-Luc 649 B-NDG
Pancreatic CFPAC-1 43, 394 nude
Neuroblastoma COA6 484, 565, 763, 838, 898 NOD.SCID, nude
Prostate LuCap136 812 nude
Ovarian OVA-1 91 SCID
Osteosarcoma Saos-2 692, 984 R2G2
Multiple Myeloma NCI-H929 489, 493 NOD.SCID
Ovarian OVCAR-3 39, 73, 98, 99, 45, 456, 631, 668 NMRI nude, nude, SCID-beige
Ovarian PA354 143 nude, SCID-beige
Pancreatic PANC-1-luc 572 nude
Oral squamous cell carcinoma HSC-3 GFP/Luc 620, 829 nude
Pancreatic MIA PaCa-2, 54, 167, 277, 420, 558,572, 595, 604, 652, 879 nude, B-NDG
Prostate LuCap35 143 nude, SCID-beige
Prostate C4-2 513, 583, 859, 865 nude
Prostate LuCap73 812 nude
Multiple Myeloma OPM-2 489 NOD.SCID
Pancreatic 053M 709 nude
Prostate LNCaP 50, 104, 105, 106, 194, 223, 246, 326, 410, 430, 494, 594, 609, 671, 714, 725, 731, 755, 915 nude, C.B-17 SCID, SCID, NOD.SCID, SCID-beige
Pancreatic T3M4 42 nude
Ovarian CAOV3 87 nude
Prostate BPH1 915 CB.17-SCID
Prostate MDA-PCa-2b 143 nude, SCID-beige
Prostate DU-145 29, 211, 221, 679, 943 ICR-SCID, nude, SCID-beige
Lung PC-9/BRc1 351 nude
Pancreatic AsPC-1 299, 709, 818, 852 nude nude
Lymphoma CA46 144 SCID
Lymphoma (PCNSL-primary CNS lymphona) PCNSL-14 615 nude
Lymphoma MUTU-1 398 C.B-17 SCID
Lung NCI-N417 32 nude
Multiple Myeloma JJN3 497 NOD.SCID
Lymphoma U2932 751 NOD.SCID
Lymphoma (PCNSL-primary CNS lymphona) PCNSL-12 615 nude
Melanoma SK-MEL23/155 495 NOD.SCID
Prostate PC3M-Luc 560, 950 nude
Prostate PC-3M 164 nude
Ovarian SKOV-luc 981 Balb/c nude
Lung NCI-H1915 694 R2G2, Nude
Pancreatic BxPC3/vector 276, 280 nude
Oral 686LN 279 nude
Sarcoma SK-LMS-1 523 nude
Patient-Derived Tumors (Human Tissue)
Carcinoma (Intrahepatic cholangiocarcinoma) PDX0044 (ICC PDX) 540 B-NDG
Colorectal (PTEN mutant PDX) 332 NMRI nude
Colorectal CUCRC036 338 nude
Ewing Sarcoma HSJD-ES-002 885 nude
Lung CTG-2011 847 nude
Glioblastoma GMB-07 475 NOD.SCID
Lung CTG-0166 847 nude
Leukemia (acute myeloid leukemia (AML) PDX 804 B-NDG
Neuroblastoma PC9GR 602 nude
Glioblastoma GSC827 703, 919 nude
Breast WHIM14 (basal-like) 689 SCID-beige
Colorectal CUCRC042 338 nude
Oral (Floor of Mouth Squamous Cell Carcinoma PDX) 395 nude
Breast WHIM20 (luminal) 689 SCID-beige
Lung CTG-0159 847 nude
Endometrial NCI-H441 681 SCID-beige
Embryonal RMS Rh-18, Rh-36 715 C.B-17 SCID
Lung CTG-1612 847 nude
Various (Adrenal, pancreatic, colon, breast) PDX 874 nude
Prostate 3B 333 nude
Ovarian PM-LGSOC-01 684 SCID-beige
Pancreatic CTG-0359 856 nude
Breast HCI-002 683 SCID-beige
Breast MC-BR-BTY-0030 857 nude
Breast HBCX 7 270 nude
Brain (PDX) 271, 426, 626, 662 nude, C.B-17 SCID nude
Breast HBCX 1 270 nude
Breast HMCC-3186 683 SCID-beige
Breast HBCX 12B 270 nude
Breast HIM3 526 nude
Breast HMCC-3555 683 SCID-beige
Breast PDX60 349 NMRI nude
Breast HBCX 9 270 nude
Ovarian (ovarian, primary peritoneal, or fallopian tube cancer PDX) 437, 438, 681, 954, 968 SCID-beige, nude
Lung UW-Lung-21 836 nude
Ovarian PH423 732 SCID-beige
Prostate (PDX) 675 NOD.SCID
Pancreatic CTG-0064 856 nude
Ovarian PH397 732 SCID-beige
Sarcoma (Chondrosarcoma PDX) 334 nude, C.B-17 SCID
Sarcoma (Leiomyosarcoma PDX) 334 nude
Pancreatic CTG-0759 856 nude
Prostate 4T 333 nude
Prostate C4-2B 452, 714 CB-17
Pancreatic CTG-0081 856 nude
Thyroid CUTC5 470, 505 SCID-beige, nude
Pancreatic Panc194 335 nude
Wilms Tumor KT-10, KT-11, KT-13, KT-5 715 C.B-17 SCID
Ovarian PH341 732 SCID-beige
Colorectal CUCRC125 336 nude
Melanoma H2 488 NOD.SCID
Glioblastoma GBM143 592 nude
Lung CTG-1212 847 nude
Lung UW-Lung-16 836 nude
Lung PC9GROR 602 nude
Colorectal CUCRC108 (KRAS mutant PDX) 336 nude
Neuroblastoma COG-N-415x, COG-N421x, COG-N-452x, COG-N-453x, COG-N-480x, COG-N-496x, COG-N-519x, COG-N-416x-Felix-PDX, NB-1643, NB-1691, NB-Ebc, NB-SD 715 C.B-17 SCID
Colorectal (KRAS mutant PDX) 332 NMRI nude
Lung UW-Lung-5 836 nude
Ovarian PH454 732 SCID-beige
Ovarian PH370 732 SCID-beige
Lung CTG-1535 847 nude
Pancreatic PDX 613, 700 nude, B-NDG B2m KO
Breast PDX-1079 474 CB-17
Brain 15-037 (GBM PDX) 658 C.B-17 SCID
Breast PDX-1173 474 CB-17
Ovarian PAPP-A 457 SCID-beige
Sarcoma (Phyllodes sarcoma PDX) 334 nude
Prostate KRAS PANC-1 459 SCID-beige
Pancreatic CTG-0358 856 nude
Pancreatic CTG-0083 856 nude
Sarcoma (Myxoma PDX) 334 nude
Sarcoma (Small round cell sarcoma PDX) 334 nude
Pancreatic CTG-0069 856 nude
Various (Lung, Gastric, Esophageal, Lymphooma, Bladder, Pancreatic, Head and Neck) PDX 878, 980 nude
Ovarian PH578 687 SCID-beige
Pancreatic PC13 589 nude
Pancreatic CTG-0440 856 nude
Pancreatic CTG-0289 856 nude
Prostate C4-2BENZR 731 SCID-beige
Prostate LuCaP-23.1 583 nude
Ovarian (High Grade Serous) PDX PH039 730 SCID-beige
Sarcoma (Ewing sarcoma PDX) 334, 662 nude
Pancreatic CTG-0101 856 nude
Sarcoma (Multifocal sarcoma PDX) 334 nude
Pancreatic CTG-0068 856 nude
Ovarian PH212 467 SCID-beige
Pancreatic CTG-0416 856 nude
Prostate 1B 333 nude
Thyroid TPC-1 448, 463, 628 SCID-beige, nude nude
Pancreatic CTG-0103 856 nude
Ovarian PH747 732 SCID-beige
Breast BCM-4272 469, 683 SCID-beige
Breast HBCx-3 339 BALB/c nude
Breast HCI-010 442 NOD.SCID
Breast HBCx-30 339 BALB/c nude
Breast HBCX 17 270 nude
Breast BCM-5471 683 SCID-beige
Breast PDX291 844 nude
Breast BR-05-014E 880 nude
Breast BCM-2147 440, 577, 683 SCID-beige, nude
Breast BCM-2277 577 nude
Breast MC1 274, 683 SCID-beige
Breast BMC-2147 274 SCID-beige
Breast BCM-4888 469, 683 SCID-beige
Glioma GMB-derived 485 NOD.SCID
Head & Neck Squamous Cell Carcinoma (HNSCC) PDX-SE3 490 NOD.SCID
Breast PyMT-M-ICBR 473 SCID-beige
Ewing Sarcoma HSJD-ES-011 885 nude
Head & Neck Squamous Cell Carcinoma (HNSCC) PDX-SE1 490 NOD.SCID
Melanoma H10 488 NOD.SCID
Osteosarcoma OS-1, OS-2, OS-9, OS-31, OS-33, CPRIT-0522-000 715 C.B-17 SCID
Colorectal CUCRC040 (KRAS mutant PDX) 336 nude
Colorectal (BRAF mutant PDX) 332 NMRI nude
Lung UW-Lung-4 836 nude
Lung UW-Lung-3 836 nude
Lung UW-Lung-18 836 nude
Lung CTG-0178 847 nude
Ewing Sarcoma HSJD-ES-016 885 nude
Ewing Sarcoma HSJD-ES-012 885 nude
Pancreatic CTG-0062 856 nude
Sarcoma (Spindle cell sarcoma PDX) 334 nude
Thyroid BCPAP 448 nude
Sarcoma (Rhabdomyosarcoma PDX) 334, 662 nude, C.B-17 SCID
Sarcoma (Synovial sarcoma PDX) 334 nude
Hepatoblastoma CPRIT-1957 715 C.B-17 SCID
Breast HCC1428 499 NOD.SCID
Breast PyMT-N 473 SCID-beige
Colorectal CUCRC047 338 nude
Breast TNBC (KRAS WTPDX) 659 C.B-17 SCID
Breast WHIM18 (luminal) 689 SCID-beige
Pancreatic CTG-0088 856 nude
Pancreatic CGT-06552 856 nude
Pancreatic CTG-0360 856 nude
Pancreatic CTG-0492 856 nude
Ovarian PH048 467 SCID-beige
Prostate C4-2B-TaxR 452 CB-17
Thyroid CUTC61 470, 505 SCID-beige, nude
Pancreatic CTG-0314 856 nude
Prostate 2T 333 nude
Pancreatic CTG-0067 856 nude
Prostate DU145-TaxR 452 CB-17
Prostate 4B 333 nude
Pancreatic JH033 272 nude
Ovarian PH026 467, 690 SCID-beige
Rhaboid KT-12, KT-14, KT-16, NCH-RBD-1, NCH-RBD-2 715 C.B-17 SCID
Pancreatic CTG-0796 856 nude
Ovarian PH538 732 SCID-beige
Sarcoma (Liposarcoma PDX) 334 nude
Pancreatic CTG-0129 856 nude
Thyroid CUTC60 470, 505 SCID-beige, nude
PXA S-12-6321 715 C.B-17 SCID
Prostate LuCaP35CR 410, 753 nude, NOD.SCID
Pancreatic CTG-0117 856 nude
Thyroid CUTC48 470, 505 SCID-beige, nude
Pancreatic CTG-0090 856 nude
Ovarian PH450 687 SCID-beige
Prostate 3T 333 nude
Breast HBCx8 880 nude
Breast MDAMB468 499 NOD.SCID
Breast BCM-4013 440, 577, 683 SCID-beige, nude
Breast HBCx-24 339 BALB/c nude
Breast PDX343 844 nude
Breast BR-05-028 880 nude
Breast HMEC 455 SCID-beige
Breast BCM-4664 683 SCID-beige
Breast PDX191 844 nude
Breast PDX325 844 nude
Breast PDX PT1-17 503 nude
Breast PDX288 844 nude
Brain U87MG (GBM PDX) 337 nude
Breast BCM-3887 469, 683 SCID-beige
Breast BCM-3107 683 SCID-beige
Breast BCM-3936 683 SCID-beige
Breast BCM-3204 683 SCID-beige
Brain GBM38-Luc-GFP 657 C.B-17 SCID
Breast HCI011 739 SCID-beige
Breast BCM-4913 683 SCID-beige
Breast MCF7 526, 966 nude
Breast A73 473 SCID-beige
Breast BCM-2665 683 SCID-beige
ARMS NCH-S13-7478, Rh-28, Rh-30, Rh-30R, Rh-65, Rh66 715 C.B-17 SCID
Breast HBCx-4A 339 BALB/c nude
Breast E0771 473 SCID-beige
Breast HBCX 6 270 nude
Breast E0771-ICBR 473 SCID-beige
Breast BCM-3963 737 SCID-beige
Breast HCI-001 442 NOD.SCID
Breast HBCx-8 339 BALB/c nude
Breast PDX156 349, 844 NMRI nude, nude
Alveolar RMS Rh-30, Rh-41 715 C.B-17 SCID
Breast PyMT-M 473 SCID-beige
Lung (Small Cell Lung Cancer) CDX3/3P, CDX18/18P, CDX20/20P, CDX42/42P, CDX8/8P, CDX17/17P 729 SCID-beige
Lung UW-Lung-2 836 nude
Multiple (breast, colon, gastric, leukemia, lung, pancreatic cancers, and particularly blood tumor samples) PDX 700 B-NDG B2m KO
Lung CTG-0160 847 nude
Ovarian OVCAR-5 610, 899 nude
Ovarian OVCAR-8 460 SCID-beige
Lung (NSCLC PDX) 272, 624 NOD.SCID, nude
Breast SUM149PT 499 NOD.SCID
Lung CTG-0165 847 nude
ERMS IRS-56, JR-1, Rh-18, RH-36, SJR-HBO11-X, SJR-HBO13758-X2, SMSCTR 715 C.B-17 SCID
Kidney (Renal Cell Carcinoma PDX) 393 nude
Lung CTG-2539 847 nude
Lung UW-Lung-7 836 nude
Melanoma H1 488 NOD.SCID
Esophageal ES2267 734 SCID-beige
CNS ATRT BT-29, BT-35, BT-39, BT-40, BT-50 715 C.B-17 SCID
Breast WHIM2 (basal-like) 689 SCID-beige
Colorectal (PIK3CA mutant PDX) 332 NMRI nude
Ovarian PH778 732 SCID-beige
Colorectal CUCRC042 (KRAS/PIK3CA mutant PDX) 336 nude
Neuroblastoma NB-1382, NB-1643 715 C.B-17 SCID
Ewing Sarcoma HSJD-ES-006 885 nude
Lung (SCLC PDX) 536, 544, 792 B-NDG
Lung CTG-0828 847 nude
Neuroblastoma SK-N-SH 451 CB-17
Liver AKH23 307 SCID-beige
Breast ZR751 499 NOD.SCID
Glioblastoma GMB-05 475 NOD.SCID
Colorectal PDX 530, 700 B-NDG, B-NDG B2m KO
Breast PDX-9327 474 CB-17
Pancreatic CTG-0065 856 nude
Prostate 2B 333 nude
Pancreatic CTG-784 856 nude
Prostate DU145 452, 862 CB-17, nude
Lung p2 SCLC PDXact 354 NOD.SCID
Melanoma H3 488 NOD.SCID
Breast TNBC (MC1) 273 NOD.SCID
Esophageal squamous cell carcinoma PDX 650 B-NDG
Colorectal CUCRC026 338 nude
Meningioma NCH-S13-5042 715 C.B-17 SCID
Breast WHIM16 685 SCID-beige
Liver KFJ18 307 SCID-beige
Leukemia (adult T-cell leukemia) PDX 801 B-NDG
Lung UW-Lung-20 836 nude
Breast WHIM9 739 SCID-beige
Colorectal CUCRC006 338 nude
Glioblastoma GMB-06 475 NOD.SCID
Ewing Sarcoma CHLA-258, ES-1, ES-2, ES-3, ES-4, ES-5, ES-6, ES-7, EW-5, EW-8, NCH-EWS-1, SK-NEP-1, TC-71,ES-1a, ES-6a, SK-NEP-1a 715 C.B-17 SCID
Glioblastoma GS7 704 nude
Breast SUM149 441, 746 SCID-beige
Rodent Tissue
Insulinoma INS-1 814 nude
Carcinoma (murine) KIL C.2 532 B-NDG
Lymphoma A20 773, 927 BALB/c
Carcinoma LY2 388 BALB/c
Breast P53-null MECs 390 BALB/c
Glioblastoma WT-GBM 596 nude
Lung LLC 798, 807, 808, 979 B-NDG, C57BL/6
Lymphoma EL4 367, 371 C57BL/6, BALB/c
Osteosarcoma K7M2 772 BALB/c
Breast 4T1-luc 366, 423, 634, 769, 770, 771 BALB/c
Bladder NBT-II 299 nude nude
Bone 501 835 nude
Breast 4T07 403, 473 BALB/c, SCID-beige
Bone T94 835 nude
Breast 4T1-mCH 639 BALB/c
Brain (murine glioblastoma) GL-261 424 C57BL/6
Brain Tu-2449 365 B6C3F1
Carcinoma B4B8 388 BALB/c
Lymphoctye (pro-B cell) Ba/F3 606, 949 nude
Breast T11 473 SCID-beige
Esophageal NMBA-induced esophageal tumors 360, 361 Fischer 344
Prostate Tgfbr2floxE2 376 C57BL/6
Mammary Adenocarcinoma 13762 MAT B III 774 F344 Rats
Breast EMT6-LUC 634, 769 BALB/c
Fibrosarcoma MCA205 561, 593, 599 nude
Brain (Glioma) hamNSC-TTR 806 AURA
Brain RT2-GFP 356 Fischer 344
Brain (Glioma) CT-2A 855, 934 nude
Brain (rat glioma) C6 58, 59, 78, 140, 180 NOD.SCID, nude
Brain (murine glioma) RG2 528 RAG2 KO(SD)
Bone Tom3 835 nude
Breast 4T1-PD1 750 NOD.SCID
Breast 67NR 473 SCID-beige
Breast MMTV-PyMT 418, 673 nude, NOD.SCID
Fibrosarcoma NIH3T3 ETV6-NTRK3 653 C.B-17 SCID
Mammary MNU-induced mammary tumors 363 Sprague Dawley
Melanoma D4M.3A 971 C57BL/6
Oral (murine) PCI-13 498 NOD.SCID
Liver MC38-Luc1 387 C57BL/6
Colon CT26 391 BALB/c
Embryo (murine) Src3T3 299 nude nude
Breast 4T1-PLVX 761 NOD.SCID
Melanoma Ret melanoma 938 C57BL/6
Lymphoma E.G7 384 C57BL/6J, BALB/c
Melanoma B2905 971 C57BL/6
Colon AOM-induced colon tumors 358, 359, 364 Fischer 344
Kidney RENCA-luc 983 Balb/c
Oral (murine) MmuPV1 (papilloma virus) 554 nude
Melanoma B16-OVA 372, 375 C57BL/6
Breast 4T1 379, 381, 382, 390, 473, 477, 627, 635, 636, 637, 639, 640, 731, 750, 764, 765, 766, 767, 768, 924, 975, 977 BALB/c, SCID-beige, NOD.SCID
Bladder AY-27 357 Fischer 344
Brain (Glioma) GL261 855, 934, 937 nude
Breast 4T1-GFP 750 NOD.SCID
Colon CT26 367, 369, 380, 383, 386, 391, 635, 638, 639, 768, 923, 929, 930, 932, 974 C57BL/6, BALB/c
Breast EMT6 673, 925, 931 NOD.SCID
Mammary (rat) DMBA-induced rat mammary carcinoma 301 nude
Lung Cancer LL 371 C57BL/6
Ovarian MOSEC 970 C57BL/6
Breast JC 384 C57BL/6J, BALB/c
Lung (Small Cell Lung Cancer) KP1-EGFP 828 nude
Colorectal AOM-induced colon tumors 362 Fischer 344
Breast MMTV-PyMT/RANK+/Tg 821 nude
Carcinoma (murine mammary) 4T1 472 SCID-beige, BALB/c
Lung (murine) LL2 10 nude
Lymphoma E.G7-OVA 373 C57BL/6
Pancreatic Panc02 367, 374, 377, 933 C57BL/6, BALB/c
Fibrosarcoma MCA205-luc 599 nude
Mouse mammary adenocarcinoma TS/A 641 BALB/c
Multiple Myeloma 5TGM1 799 B-NDG
Lung 889-S1 798 B-NDG
Colon MC38 735, 841, 936, 974 SCID-beige
Melanoma B16.F10 375 C57BL/6
Melanoma Mel-14 895 SCID-beige
Melanoma (murine) B16F10 35, 36, 250, 392, 928 beige-nude-xid, nude
leiomyosarcoma DDT1-MF2 805 AURA
Ovarian ID8 610 nude
Ovarian (rat) PROb 78 nude
Fibrosarcoma Rat1-myr-p110α 881 nude
Oral (murine) MmuPV1 (papilloma virus) 666 nude
Breast MMTV-PyMT/RANK-/- 557 nude
Breast p53R249S 761 NOD.SCID
Pancreatic E6E7-Kras-st 882 nude
Mouse embryonic stem cells induced hematopoietic endothelial cells (iHECs) 648 B-NDG
Pancreatic Atmfl/fl; LSL-KrasG12D/+; Ptf1aCre/+ (AKC) cells 569 nude
Mouse mammary adenocarcinoma AT3 682 SCID-beige
Glioma BT4C 622 nude
Ovarian CHO-hCXCR4 831 nude
Ovary CHO.K1 926 BALB/c
Melanoma B16-F10 368, 370, 699, 768, 809, 820, 933, 952 C57BL/6, R2G2
Pancreatic Hapt1 805, 939 B-NDG AURA
Carcinoma (murine) LL/2 472 SCID-beige
Mammary (rat) 17β-estradiol-induced mammary tumors 355 Brown Norway
Brain (Glioma) GL261-5 855 nude
Colon CT26CL25 385 BALB/c
Melanoma B16.OVA 373 C57BL/6
Colon C51 mouse colon cancer cells 447 nude
Melanoma B16 367, 369, 378, 456, 875 C57BL/6, BALB/c, SCID-beige
Stem Cells (Human Tissue)
Central Nervous System Neural stem cells 921 nude


References

1. Verhoef, J.J.C. et al., Radiat Oncol, 2, 38 (2007). Netherlands (athymic nude mice )
2. Ponthan, F. et al., Oncol Reports, 10, 1587 (2003). Netherlands (athymic nude rats)
3. Rubenstein, J.L. et al., Neoplasia, 2(4), 306 (2000). North America (athymic nude rats)
4. Plunkett, R.J. et al., J Neurosurg, 90, 1071 (1999). North America (athymic nude rats)
5. Brignole, C. et al., J Natl Cancer Inst, 96, 1171 (2004). Italy (athymic nude mice, SCID-beige mice)
6. Pan, Y. et al., Breast Cancer Res, 8, R63 (2006). North America (athymic nude mice)
7. Sartorius, C.A. et al., Cancer Res, 65(21), 9779 (2005). North America (athymic nude mice)
8. Arteaga, C.L. et al., Cell Growth & Diff, 4, 193 (1993). North America (athymic nude mice)
9. Hardman, E.W. et al., Cancer Cell Intl, 2, 10 (2002). North America (athymic nude mice)
10. Amiekhosravi, A. et al., Thromb Haemost, 90, 549 (2003). North America (athymic nude mice)
11. Dikmen, Z.G. et al., Turk J Med Sci, 35, 65 (2005). North America (athymic nude mice )
12. Richert, M.M. et al., Breast Cancer Res, 7, R819 (2005). North America (athymic nude mice)
13. Burch, S. et al., J Biomedical Optics, 10, 034011-1-13 (2005). North America (athymic nude rats)
14. Blask, D.E. et al., Breast Cancer Res, And Treatment 79, 313 (2003). North America (athymic nude rats)
15. Bäuerle, T. et al., Intl J Oncol, 28, 573 (2006). Germany (athymic nude rats)
16. Prewett, M.C. et al., Clin Cancer Res, 8, 994 (2002). North America (athymic nude mice)
17. Sheng, H. et al., J Clin Invest, 99, 2254 (1997). North America (athymic nude mice )
18. Yang, M. et al., Proc Nat Acad Sci, 102, 6027 (2005). North America (athymic nude mice )
19. Park, B.H. et al., Proc Natl Acad Sci, 98, 2598 (2001). North America (athymic nude mice )
20. Kruskal, J.B. et al., Radiology, 215, 852 (2000). North America (athymic nude mice)
21. Tijink, B.M. et al., J Nucl Med, 47, 1127 (2006). EU (athymic nude mice)
22. Marchal, F. et al., Oncology Reports, 14, 1203 (2005). France (athymic nude rats)
23. Wang, M. et al., World J Gastroenterol, 9(11), 2627 (2003). France (athymic nude rats)
24. Dauchy, R. T. et al., Cancer Letters, 209, 7 (2004). North America (athymic nude rats)
25. Svechnikova, I. et al., Intl J Oncol, 22, 579 (2003). Netherlands (athymic nude rats)
26. Till, H. et al., Surgical Endoscopy, 19, 1483 (2005). Germany (athymic nude rats)
27. Barone, T.A. et al., Blood, 90, 298 (1997). North America (athymic nude rats)
28. Francisco, J.A. et al., Blood, 102, 1458 (2003). North America (SCID mice)
29. Geldhof, A.B. et al., Clin & Experimental Metastasis, 16(5), 447 (1998). North America (ICR-SCID mice)
30. Wang, M. et al., Blood, 109, 5455 (2007). North America (SCID mice)
31. Zou, Y. et al., J Natl Cancer Inst, 90, 1130 (1998). North America (athymic nude mice)
32. Maneckjee, R. and Minna, J.D., Proc Natl Acad Sci, 89, 1169 (1992). North America (athymic nude mice)
33. Weinberg, O.K. et al., Cancer Res, 65, 11287 (2005). North America (athymic nude mice)
34. Boehle, A.S. et al., Intl J Cancer, 94, 420 (2001). Germany (SCID-beige mice)
35. Horton, H.M. et al., Proc Natl Acad Sci, 96, 1553 (1999). North America (athymic nude mice, beige-nude-xid mice)
36. Malafa, M.P. et al., Annals of Surgical Oncol, 9(10), 1023 (2002). North America (athymic nude mice)
37. Bromberg, M.E. et al., Proc Natl Acad Sci, USA 92, 8205 (1995). North America (SCID mice)
38. Modesitt, S.C. et al., Clin Cancer Res, 7,1487 (2001). North America (athymic nude mice)
39. Duyndam, M.C.A. et al., Am J Pathol, 160, 537 (2002). Netherlands (athymic nude mice)
40. Gossmann, A. et al., J Obstetrics and Gynecol, 183, 956 (2000). North America (athymic nude rats)
41. Mahasreshti, P.J. et al., Clin Cancer Res, 7, 2057 (2001). North America (SCID mice)
42. Fukasawa, M. and Murray, K., Clin Cancer Res, 10, 3327 (2004). North America (athymic nude mice)
43. Koehler, J.A. and Drucker, D.J., Diabetes, 55, 1369 (2006). North America (athymic nude mice)
44. Weber, D. et al., Cancer Res, 60, 5284 (2000). North America (athymic nude mice)
45. Boenicke, L. et al., J Mol Med, 81, 205 (2003). Germany (SCID mice)
46. Zhang, X. et al., J Nucl Med, 47, 492 (2006). North America (athymic nude mice)
47. Tuomela, J.M. et al., BMC Cancer, 8, 81 (2008). Germany (athymic nude mice)
48. Srivastava, S.K. et al., Carcinogenesis, 24(10), 1665 (2003). North America (athymic nude mice)
49. Hillman, G.G. et al., Mol Cancer Ther, 3, 1271 (2004). North America (athymic nude mice)
50. Graff, J.R. et al., J Biol Chem, 275, 24500 (2000). North America (athymic nude mice)
51. Gregory, C.W. et al., Cancer Res, 61, 2892 (2001). North America (athymic nude mice)
52. Cabrera, G. et al., Mol Cancer, 5, 32 doi:10.1186/1476-4598-5-32 (2006). North America (athymic nude rats)
53. Adkins, H.B. et al., J Clin Invest, 112, 575 (2003). North America (athymic nude mice)
54. Weydert, C. et al., Mol Cancer Ther, 2, 361 (2003). North America (athymic nude mice)
55. Fu, X, Tao, L and Zhang, X., Cancer Gene Therapy, 14, 480 (2007). North America (athymic nude mice)
56. Sun, L. and Chen, C., J Biol Chem, 272(40), 25367 (1997). North America (athymic nude mice)
57. Sutherland, M.K. et al., mAbs 1(5), 481 (2009). North America (SCID mice)
58. Lai, C.P.K. et al., Cancer Res, 67(4), 1545 (2007). North America (athymic nude mice)
59. Folkins, C. et al., Cancer Res, 69(18), 7243 (2009). North America (athymic nude mice)
60. Ueno, N.T. et al., Cancer Res, 62, 6712 (2002). North America (athymic nude mice)
61. agata, Y. et al., Cancer Cell, 6, 117 (2004). North America (athymic nude mice )
62. Puig, T. et al., Clin. Cancer Res., 15, 7608 (2009). UK (BALB/c nude mice )
63. Liu, Z. et al., Nano Res, 3(3), 222 (2010). North America (athymic nude mice)
64. Chandarlapaty, S. et al., Oncogene, 29, 325 (2010). EU (athymic nude mice)
65. Simons, A.L. et al., Int J Radiat Oncol Biol Phys, 69(4), 1222 (2007). North America (athymic nude mice)
66. Want, D. et al., Clin Cancer Res, 14(19), 6228 (2008). North America (athymic nude mice)
67. LoTempio, M.M. et al., Clin Cancer Res, 11(19), 6994 (2005). North America (athymic nude mice)
68. Barok, M. et al., Mol Cancer Ther, 6(7), 2065 (2007). Netherlands (NMRI nude mice, SCID mice)
69. Tanner, M. et al., Mol Cancer Ther, 3(12), 1585 (2004). Netherlands (NMRI nude mice)
70. Tanner, M. et al., Annals of Oncol, 16, 273 (2005). Netherlands (NMRI nude mice)
71. Lin, L. et al., Neoplasia, 12(1), 39 (2010). North America (athymic nude mice)
72. Moulder, S.L. et al., Cancer Res, 61, 8887 (2001). North America (athymic nude mice)
73. Zhang, X. et al., Clin Cancer Res, 11, 323 (2005). North America (athymic nude mice)
74. Campbell, R.A. et al., Int J Oncol, 28(6), 1409 (2006). North America (athymic nude mice)
75. Chen, H. et al., Blood, 113, 1992 (2009). North America (athymic nude mice)
76. Dingli, D. et al., Clin Cancer Res, 8, 3948 (2002). North America (SCID mice)
77. Chavez-Blanco, A. et al., Cancer Cell Int, 6, 2 (2006). North America (athymic nude mice)
78. Ferretti, S. et al., Neoplasia, 11(9), 874 (2009). EU (athymic nude mice)
79. Heikkilä, J.E. et al., PLoS ONE, 5(1), e8603 (2010). UK (BALB/c nude mice)
80. Xiao, W. et al., Eur J Nucl Med Mol Imaging, 36, 94 (2009). North America (athymic nude mice)
81. Li, L. et al., Clin Cancer Res, 13(7), 2178 (2007). North America (athymic nude mice)
82. Hsu, A.R. et al., J Nucl Med, 48, 445 (2007). North America (athymic nude mice)
83. Chen, X. et al., J Nucl Med, 45, 1776 (2004). North America (athymic nude mice)
84. Menon, C. et al., Am J Physiol Heart Circ Physiol, 24, H317 (2003). North America (athymic nude mice)
85. Ueno, T. et al., Mol Cancer Ther, 5(3), 732 (2006). North America (athymic nude rats)
86. Goyeneche, A.A. et al., Clin Cancer Res, 13(11), 3370 (2007). North America (athymic nude mice)
87. Li, D. et al., Oncogene, 21, 2805 (2002). North America (athymic nude mice)
88. Boehle, A.S. et al., Ann Thorac Surg, 69, 1010 (2000). Germany (SCID-beige mice)
89. Kurdow, R. et al., Ann Thorac Surg, 73, 905 (2002). Germany (SCID-beige mice)
90. Hamblett, K.J. et al., Clin Cancer Res, 10, 7063 (2004). North America (SCID mice)
91. Santin, A.D. et al., Cancer Res, 65(10), 4334 (2005). North America (SCID mice)
92. Nilsson, M.B. et al., J Biol Chem, 282(41), 29919 (2007). North America (SCID mice)
93. Spaeth, E.L. et al., PloS ONE, 4(4), e4992 (2009). North America (SCID mice)
94. Bruckheimer, E.M. et al., Neoplasia, 11(6), 509 (2009). North America (SCID mice, NOD.SCID mice)
95. Nagengast, W.B. et al., J Nucl Med, 48, 1313 (2007). Netherlands (athymic nude mice)
96. Auzenne, E. et al., Neoplasia, 9(6), 479 (2007). North America (athymic nude mice)
97. Rodrigues-Ferreira, S. et al., PLoS ONE, 4(10), e7239 (2009). UK (SCID mice)
98. Houba, P.H.J. et al., British J Cancer, 78(12), 1600 (1998). Netherlands (athymic nude mice)
99. Vingerhoeds, M.H. et al., British J Cancer, 74, 1023 (1996). Netherlands (NMRI nude mice)
100. Le Pimpec-Barthes, F. et al., British J Cancer, 81(8), 1344 (1999). EU (athymic nude rats)
101. Fu, X. et al., Mol Ther, 7(6), 748 (2003). North America (athymic nude mice)
102. Folberg, R. et al., Invest Ophthalmol Vis Sci, 48(7), 2967 (2007). North America (SCID mice)
103. Swami S., et.al., Horm Cancer. 2011 June 1; 2(3): 190-202. North America (athymic nude mice)
104. Kiyama, S. et al., Cancer Res, 63, 3575 (2003). North America (athymic nude mice)
105. Elsadek, B. et al., Prostate Cancer and Prostatic Diseases, 14, 14 (2011). Germany (SCID mice)
106. Sun, S. et al., J Clin Invest, 120(8), 2715 (2010). North America (athymic nude mice)
107. Li, T.H. et al., Nucleic Acids Res, 35(8), 2767 (2007). North America (athymic nude mice)
108. Pan, J. et al., PLoS ONE, 5(10), e13298. doi:10.1371/journal.pone.0013298 (2010). North America (athymic nude mice)
109. Määttä, A.-M. et al., Int J Cancer, 121, 863 (2007). Netherlands (NMRI nude mice)
110. Jarzynka, M.J. et al., Int J Oncol, 28(2), 337 (2006). North America (athymic nude mice)
111. Bruckheimer, E.M. et al., Neoplasia, 11(6), 509 (2009). North America (athymic nude mice, SCID mice, NOD.SCID mice)
112. Yi, J. M. et al., Cancer Res, 68(19), 8094 (2008). North America (SCID mice)
113. Ovalle, S. et al., Int J Cancer, 121, 2140 (2007). Spain (athymic nude mice )
114. Schleup, T. et al., Clin Cancer Res, 15, 181 (2009). North America (athymic nude mice )
115. Orian-Rousseau, V. et al., Int J Cancer, 113, 699 (2005). Germany (SCID-beige mice)
116. Zielske, S.P. et al., Int J Radiat Oncol Biol Phys, 75(3), 843 (2009). North America (athymic nude mice)
117. Kaafarani, I. et al., FASEBJ, 23, doi: 10.1096/fj.08-127852 (2009). France (NMRI nude mice)
118. Koskimaki, J. E. et al., BMC Cancer, 10, 29 (2010). North America (athymic nude mice)
119. Jakubezak, J.L. et al., Cancer Res, 63, 1490 (2003). North America (athymic nude mice)
120. McEarchern, J.A. et al., Clin Cancer Res, 14, 7763 (2008). North America (SCID mice)
121. Kelley, S.K. et al., Br J Pharmacol, 148(8), 1116 (2006). North America (SCID mice)
122. Smrekar, B. et al., Gene Therapy, 10, 1079 (2003). UK; Germany (SCID mice)
123. Tremmel, M. et al., Blood, 114(25), 5236 (2009). Germany (athymic nude mice)
124. Cuesta, Á.M., et al., PLoS ONE, 4(4), e5381. doi:10.1371/journal.pone.0005381 (2009). Spain (athymic nude mice)
125. Pastorino, F. et al., Cancer Res, 63, 86 (2003). Italy (athymic nude mice )
126. Kelly, P. et al., British J Cancer, 103, 232 (2010). UK (SCID mice)
127. Larkin, J.O. et al., Ultrasound Med Biol, 34(3), 406 (2008). UK (MF1 nude mice)
128. Kang, K.S., et al., PLoS ONE 5(4): e10296. doi:10.1371/journal.pone.0010296 (2010). North America (athymic nude mice)
129. Shah, G.V. et al., Endocrine-Related Cancer, 15, 953 (2008). North America (athymic nude mice)
130. Lipnik, K. et al., Virol, 349, 121 (2006). Germany (SCID-beige mice)
131. Agu, C.A. et al., J Gene Med, 8, 229 (2006). Germany (SCID-beige mice)
132. Rhodes, L.V. et al., Breast Cancer Res Treat, 121(2), 293 (2010). North America (SCID-beige mice)
133. Barone, T.A. et al., J Neuro-Oncol, 95(1), 37 (2009). North America (athymic nude rats)
134. Nanda, D. et al., Cancer Res, 61, 8743 (2001). UK (beige-nude-xid mice)
135. Markaverich, B. et al., Eviron Health Perspect,110, 169 (2002). North America (athymic nude mice)
136. Stan, S.D. et al., Cancer Res, 68(18), 7661 (2008). North America (athymic nude mice)
137. Shashkova, E.V. et al., Cancer Res, 68, 5896 (2008). North America (athymic nude mice)
138. Larkin, J.O. et al., Ann Surg, 245(3), 469 (2007). UK (BALB/c nude mice, MF1 nude mice)
139. Loebinger, M.R. et al., Cancer Res, 69(23), 8862 (2009). UK (NOD.SCID mice)
140. Cai, W. et al., J Nucl Med, 48, 304 (2007). North America (athymic nude mice)
141. Squires, M.S. et al., Mol Cancer, 8(2), 324 (2009). UK (BALB/c nude mice)
142. Airoldi, I. et al., PLoS ONE, 4(7), e6119. doi:10.1371/journal.pone.0006119 (2009). Italy (NOD.SCID mice)
143. Lee, F.Y.F. et al., Cancer Chemother Pharmacol, 63, 201 (2009). North America (athymic nude mice, SCID-beige mice)
144. Yang, J. et al., Cancer Cell, 10, 295 (2006). North America (SCID mice)
145. Dauchy, R.T. et al., J Pineal Res, 47, 32 (2009). North America (athymic nude rat)
146. Wu, J. et al., Cancer Res, 71, 2622 (2011). North America (athymic nude rat)
147. Sharma, S. et al., Ejc Supplements, ISSN:13596349, 8(7), 66 (2010). North America (athymic nude mice)
148. Hadaschik, B.A. et al., Cancer Res, 68, 4506 (2008). North America (athymic nude mice)
149. Chadalapaka, G. et al., Cancer Res, 68(13), 5345 (2008). North America (athymic nude mice)
150. Cho, S.D. et al., Mol Pharmacol, 77(3), 396 (2010). North America (athymic nude mice)
151. Jutooru, I. et al., Exp Cell Res, 316(13), 2174 (2010). North America (athymic nude mice)
152. Zawel, L. et al., PNAS, 99(5), 2848 (2002). North America (athymic nude mice)
153. Donawho, C.K. et al., Clin Cancer Res, 13(9), 2728 (2007). North America (athymic nude mice)
154. Rockett, J.C. et al., Br J Cancer, 75(2), 258 (1997). UK (athymic nude mice)
155. Kan, T. et al., Gastroenterol, 136(5), 1689 (2009) North America (athymic nude mice)
156. Zhang, S. et al. Mol Cancer Ther, 11, 108 (2012). North America (athymic nude mice)
157. Zhang, K.-X. et al., Breast Cancer Res Treat, 125, 89 (2011). North America (athymic nude mice)
158. Zhang, K.-X. et al., Breast Cancer Res Treat, 125, 89 (2011). North America (athymic nude mice)
159. Liu, Z. et al., Nano Res, 3, 222 (2010). North America (athymic nude mice)
160. Rimawi, M.R. et al., Clin Cancer Res, 17, 1351 (2011). North America (athymic nude mice)
161. Zhao, Y. et al., Cancer Res, 71, 4585 (2011). North America (athymic nude mice)
162. Scaltriti, M. et al., Mol Cancer Ther, 10, 817 (2011). North America (athymic nude mice)
163. Massey, A.J. et al., Mol Cancer Ther, 9, 906 (2010). Switzerland (athymic nude mice)
164. Maira, S.-M. et al., Mol Cancer Ther, doi:10.1158/1535-7163.MCT-11-0474. Switzerland (athymic nude mice)
165. O'Donovan, N. et al., Invest New Drugs, 29, 752 (2011). UK (BALB/c nude mice)
166. Chao, O. et al., J Med Chem, 52, 7808 (2009). North America (athymic nude mice)
167. Yu, Y.A. et al., Mol Cancer Ther, 8, 141 (2009). North America (athymic nude mice)
168. Haddad, D. et al., J Translational Med, 9, 36 (2011). North America (athymic nude mice)
169. Gourdeau, H. et al., Cancer Chemother Pharmacol, 61, 911 (2008). North America (athymic nude mice)
170. Liu, T.W. et al., Bioconjugate Chem, 22, 1021 (2011). North America (athymic nude mice, athymic nude rats)
171. Alzani, R. et al., Exp Hematol, 38, 259 (2010). Italy (SCID mice)
172. Sehdev, V. et al., Mol Cancer Ther, doi: 10.1158/1535-7163.MCT-11-0623 (2012). North America (athymic nude mice)
173. Bralten, L.B.C. et al., Ann Neurol, 69, 455 (2011). Netherlands (SCID mice)
174. Ayuzawa, R. et al., Cancer Letters,280, 31 (2009). North America (SCID mice)
175. Barok, M. et al., Cancer Letters, 306, 171 (2011). Netherlands (SCID mice)
176. Zeng, Q. et al., Euro J Cancer, 46, 1132 (2010). North America (athymic nude mice)
177. Pais, A. et al. Cancer Res, 71(24), 7387 (2011). Israel (SCID mice)
178. Junttila, T.T. et al., Cancer Cell, 15, 429 (2009). North America (SCID mice)
179. Daigle, S. R. et al., Cancer Cell, 20, 53 (2011). North America (athymic nude mice)
180. Patyna, S. et al. Mol Cancer Ther, 5, 1774 (2006). North America (athymic nude mice, NOD.SCID mice)
181. Zarrinkar, P.P. et al. Blood, 114(14), 2984 (2009). North America (NOD.SCID mice)
182. Mertz, J.A. et al., PNAS, 108(40), 16669 (2011). North America (athymic nude mice)
183. Tokalov, S.V. et al., J Biomed and Biotechnol, Article ID 580531, 4 p doi:10.1155/2010/580531 (2010). Germany (athymic nude rats)
184. Anastas, J.N. et al., Oncogene, doi:10.1038/onc.2011.528 (2011). North America (athymic nude mice)
185. Mitra, A. et al., Breast Cancer Res, 10:R22 (2008). North America (athymic nude mice)
186. Volk, L.D. et al., Neoplasia, 10(6), 613 (2008). North America (athymic nude mice)
187. Hiraga, T. et al., Cancer Res, 61, 4418 (2001). North America (athymic nude mice)
188. Mukhopadhyay, K.D. et al., PLoS ONE, 6(6), e20473 (2011). North America (athymic nude mice)
189. Bandyopadhyay, A. et al., PLoS ONE, 5(4), e10365 (2010). North America (athymic nude mice)
190. Walsh, C. et al., Cancer Biol Ther, 9(10), 778 (2010). North America (athymic nude mice, BALB/c SCID mice)
191. Lee, S.-M. et al., ACS Nano, 4(9), 4971 (2010). North America (athymic nude mice)
192. Kerjaschki, D. et al. J Clin Invest, 121(5), 2000 (2011). Germany (SCID mice)
193. Whitehurst, B. et al., Int J Cancer, 121, 2181 (2007). North America (SCID mice)
194. Graeser, R. et al., Int J Cancer, 122, 1145 (2008). Germany (SCID mice)
195. Gomez-Manzano, C. et al., Neuro-Oncol, 10, 940 (2008). North America (athymic nude mice)
196. et al., Cancer Gene Ther, 12, 947 (2005). Germany (athymic nude mice)
197. Verheije, M.H. et al., J Virol, 83(15), 7507 (2009). Netherlands (athymic nude mice)
198. Ke, L.D. et al., Clin Cancer Res, 6, 2562 (2000). North America (athymic nude mice)
199. Clark, A.J. et al., J Neurosurg, 112, 18 (2010). North America (athymic nude mice)
200. Calzolari, A. et al., Transl Oncol, 3(2), 123 (2010). Italy (athymic nude mice)
201. Schiappacassi, M. et al., Mol Cancer Ther, 7(5), 1164 (2008). Italy (athymic nude mice)
202. Yoon, H. et al., J Cellular Biochem, 108, 832 (2009). North America (athymic nude mice)
203. Abourbeh, G. et al., Nucl Med and Biol, 34, 55 (2007). Israel (athymic nude mice)
204. Benny, O. et al., FASEB J, 22, 488 (2008). Israel (CD-1 nude mice)
205. Yin, S. et al., Neuro-Oncol, 12(1), 19 (2010). Sweden (athymic nude rats)
206. Khan, Z. et al., Neuro-Oncol, 12(6), 549 Sweden (athymic nude rats)
207. Buursma, A.R. et al., J Nucl Med, 46, 2068 (2005). Netherlands (athymic nude rats)
208. Gunasekaran, K. et al., J Biol Chem, 285(25), 19637 (2010). North America (NOD.SCID mice)
209. Li, J.-L. et al., Cancer Res, 67(23), 11244 (2007). Germany (BALB/c SCID mice)
210. Holen I., et.al., Breast Cancer Research 2012, 14:R86. United Kingdom (BALB/c nude mice)
211. Hennessy, B.T. et al. Clin Cancer Res, 13(24), 7421 (2007). North America (athymic nude mice)
212. Nakamori, M. et al., 9, 2727 (2003). North America (athymic nude mice)
213. Ma, L. et al., Acta Biochim Biophys Sin, 42(9), 593 (2010). Asia (BALB/c nude mice)
214. Shao, M. et al., Cancer Res, 69, 9192 (2009). North America (BALB/c nude mice)
215. Lljin, K. et al., Clin Cancer Res, 15(19), 6070 (2009). Finland (athymic nude mice)
216. Izhak, L. et al., J Immunol, 183, 732 (2009). Israel (SCID-beige mice)
217. Inbar-Rozensal, D. et al., Breast Cancer Res, 11, R78 (2009). Israel (CD-1 nude mice)
218. González, L. et al., J Biol Chem, 281(30), 20851 (2006). Spain (athymic nude mice)
219. Wu, L. et al., Clin Cancer Res, 11(22), 8195 (2005). North America (athymic nude mice)
220. Ghosh, A.K. et al., Cancer Res, 56(3), 718 (2005). North America (athymic nude mice)
221. Tang, L. et al., J Nutr, 135, 287 (2005). North America (athymic nude mice)
222. Fu, X. et al., Gene Ther, 10, 1458 (2003). North America (athymic nude mice)
223. Shashkova, E.V. et al., Cancer Res, 68(14), 5896 (2008). North America (athymic nude mice)
224. Ozawa, T. et al., Mol Pharmaceutics, 1(5), 368 (2004). North America (athymic nude rats)
225. Bristol, J.A. et al., Mol Ther, 7(6), 755 (2003). North America (athymic nude mice)
226. Folgiero, V. et al., Cell Death and Disease, 3, e440; doi:10.1038/cddis.2012.179 (2012). Italy (athymic nude mice, SCID mice)
227. Jensen, M.R. et al., Breast Cancer Res, 10, R33 (2008). Switzerland (athymic nude mice)
228. Golubovskaya, V.M. et al., J Med Chem, 51(23), 7405 (2008). North America (athymic nude mice)
229. Hernandez-Alcoceba, R. et al., Human Gene Ther, 11, 2009 (2000). North America (athymic nude mice)
230. Gutierrez, M.C. et al., JCO, 23(11), 2469 (2005). UK (athymic nude mice)
231. Mahller, Y.Y. et al. PLoS ONE, 4(1):e4235. doi:10.1371/journal.pone.0004235 (2009). North America (athymic nude mice)
232. Zhou, Y. et al., J Biol Chem, 286, 32843 (2011). North America (athymic nude mice)
233. Salvatori, L. et al., PLoS ONE, 7(2), e31467. doi:10.1371/journal.pone.0031467 (2012). Italy (NOD.SCID mice)
234. Londoño-Joshi, A.I. et al., Breast Cancer Res Treat, DOI 10.1007/s10549-011-1763-0 (2011). North America (NOD.SCID mice)
235. Joseph, I. et al., Cancer Res, 70, 9494 (2010). North America (athymic nude mice)
236. Lonardo, E. et al., Cell Stem Cell, 9(5), 433 (2011). Spain (athymic nude mice)
237. Xiao, K. et al., Biomaterials, 30(30), 6006 (2009). North America (athymic nude mice)
238. Li, Y. et al., J Immunol, 179, 4263 (2007). North America (SCID mice)
239. Kumagai, T. et al., J Natl Cancer Inst, 95(12), 896 (2003). North America (beige-nude-xid mice)
240. Kumagai, T. et al., Clin Cancer Res, 10, 1508 (2004). North America (beige-nude-xid mice)
241. Audo, I. et al., Invest Ophthalmol Vis Sci, 44, 4192 (2003). North America (athymic nude mice)
242. Cocco, C. et al., Clin Cancer Res, 16, 4188 (2010). Italy (NOD.SCID mice)
243. Ayers, G.D. et al., J Ultrasound Med, 29(6), 891 (2010). North America (athymic nude mice)
244. Ning, S. et al., Cancer Res, 70(19), OF1 (2010). North America (athymic nude rats)
245. Yee, A.J.M. et al., Breast Cancer Res, 9(4), R47 (2007). North America (CD-1 nude mice, athymic nude rats )
246. Mercatelli, N. et al., PLoS ONE, 3(12), e4029 (2008). Italy (SCID mice)
247. Thallinger, C. et al., J Invest Dermatol, 127, 2411 (2007). Germany (SCID mice)
248. Elsner, L. et al., J Immunol, 179, 5523 (2007). Germany (SCID-beige mice)
249. Ren, G. et al., J Nucl Med, 50, 1692 (2009). North America (athymic nude mice)
250. Morello, S. et al., Neoplasia, 13(4), 365 (2011). Italy (athymic nude mice)
251. Stangl, S. et al., J Immunol, 176, 6270 (2006). Germany (SCID-beige mice)
252. Phillips, G.D.L. et al., Cancer Res, 68, 9280 (2008). North America (beige-nude-xid mice)
253. Lee-Hoeflich, S.T. et al., Cancer Res, 68, 5878 (2008). North America (beige-nude-xid mice)
254. Yao, E. et al., Clin Cancer Res, 15, 4147 (2009). North America (beige-nude-xid mice)
255. Allegrucci, C. et al., Mol Cancer, 10, 7 (2011). UK (MF1 nude mice)
256. Brachmann, S.M. et al., PNAS, 106(52), 22299 (2009). North America (athymic nude mice)
257. Hoeflich, K.P. et al., Clin Cancer Res, 15(14), 4649 (2009). North America (beige-nude-xid mice)
258. Wong, T.W. et al., Clin Cancer Res, 12(20), 6186 (2006). North America (athymic nude mice)
259. Halasi, M. et al., Cell Cycle, 9(4), 1214 (2010). North America (athymic nude mice)
260. Zhang, S. et al., Endocrine-Related Cancer, 16, 835 (2009). North America (athymic nude mice)
261. Hitosugi, T. et al., Mol Cell, 44(6), 864 (2011). North America (athymic nude mice)
262. Jimeno, A. et al., Cancer Res, 65, 3003 (2005). North America (athymic nude mice)
263. Mutsaers, A.J. et al., Clin Cancer Res, 15, 2397 (2009). North America (athymic nude mice)
264. Guix, M. et al., J Clin Invest, 118(7), 2609 (2008). North America (athymic nude mice)
265. Donnini, S. et al., Oncogene, doi:10.1038/onc.2011.503 (2011). Italy (athymic nude mice)
266. Shir, A. et al., Clin Cancer Res, 17, 1033 (2011). Israel (NOD.SCID mice)
267. Lee, C.M. et al., BMC Cancer, 10, 255 (2010). North America (athymic nude mice)
268. Alameda, J.P. et al., Cell Death and Disease, 2, e208; doi:10.1038/cddis.2011.82 (2011). Spain (athymic nude mice)
269. Valle BL, et al,. PLoS ONE 8(4): e61836 (2013). North America (athymic nude mice)
270. Zhang C.C, et.al., Clinical Cancer Research 1-12; 2012. AACR. France (athymic nude mice)
271. Carlson B. L, et.al., Curr Protoc Pharmocol. 2011 mar; Chapter 14: Unit 14. 16 (2011). North America (athymic nude mice)
272. Calles A., et.al., Curr Protoc Pharmacol. 2013 Jun; Chapter 14: Unit 14.26 (2013). North America (NOD.SCID mice, athymic nude mice)
273. Litzenburger BC., et.al., Clin Cancer Res April 15, 2011. 17; 2314. North America (NOD.SCID mice)
274. Schott AF, et.al., Clin Cancer Res clincanres.3326.2012; Published Online First January 22, 2013. North America (SCID-beige mice)
275. Leake K, et.al., PLoS ONE 7(4): e34582 (2012). North America (athymic nude mice)
276. Zhao S, et.al., Oncogenesis (2013) 2, e76. North America (athymic nude mice)
277. Hernandez JL, et.al., PLoS ONE 8(9): e72480 (2013). Spain (athymic nude mice)
278. Jager W, el.al., PLoS ONE 8(3): e59536 (2013). North America (athymic nude mice)
279. Shin D.H, et.al., JNCI J Natl Cancer Inst (2013). North America (athymic nude mice)
280. Venkatasubbarao K, et.al., Molecular Cancer 2013, 12:104. North America (athymic nude mice)
281. Rybczynska A.A, el.al., J Nucl Med September 1, 2013. The Netherlands (athymic nude mice)
282. Gholami S, et.al., Breast Cancer Research 2013, 15:R26. North America (athymic nude mice)
283. Zins K, et.al., Mol. Sci. 2013, 14, 17958-17971. Germany (athymic nude mice)
284. Benavente S, et.al., Clin Cancer Res March 1, 2009 15; 1585. North America (athymic nude mice)
285. Verhoeff JJC, et.al., Radiation Oncology 2007, 2:38. The Netherlands (athymic nude mice)
286. Alessandro GD, et.al., Cell Death and Disease (2013) 4, e773. Italy (C.B-17 SCID mice)
287. Jiang J., et.al., Oncol Rep. 2012 October; 28(4): 1139-1145. North America (athymic nude mice)
288. Koht HE., et.al., The Journal of Clinical investigation. Volume 122, number 3, March 2012. North America (athymic nude mice)
289. Barok M., et.al., Breast Cancer Research 2011, 13:R46. The Netherlands (C.B-17 SCID mice)
290. Thorner Ar., et.al., PLoS ONE 5(10)e13073. North America (athymic nude mice)
291. Hamada K., et.al., Gynecologic Oncology 99 (2005) S159-S165. North America (athymic nude rats)
292. Lheureux S., et.al. Transl Oncol. 2013 October; 6(5): 586-595. North America (athymic nude rats)
293. Millar HJ., et.al., Cancer Epidemiol Biomarkers Prev August 2008 17; 2180. North America (athymic nude rats)
294. Ayers GD., et.al., JUM June 1, 2010 vol. 29 no. 6 891-90. North America (athymic nude mice)
295. Cyran CC., et.al., PLoS ONE 8(9): e76009. North America (athymic nude rats)
296. Daigle SR., et.al., Blood 2013 122: 1017-1025. North America (athymic nude rats)
297. Jafri SH., et al., Journal of Experimental & Clinical Cancer Research 2010 29:87. North America (C.B-17 SCID mice)
298. Dingli D., et al., Blood 2003 102: 489-496. North America (C.B-17 SCID mice)
299. Green TP., et.al., Molecular Oncology 3 (2009), 248-261. France (athymic nude mice)
300. Kreider JW., at al., Cancer Research 39, 273-276, January 1979. North America (athymic nude mice)
301. Welsch CW, et.al, JNCI J Natl Cancer Inst (1987) 78 (3): 557-565. North America (athymic nude mice)
302. Park SI., et.al., Curr Protoc Pharmacol. 2010 December 1; 51: 14.15-14.15.27. North America (athymic nude mice)
303. Fernandes MS., et.al., Clin Cancer Res August 1, 2009 15; 4847. North America (C.B-17 SCID mice)
304. Mundra JJ., et.al, JPET August 2012 vol. 342 no. 2 273-287. North America (SCID mice)
305. Peng KW., et.al., Blood, 1 October 2001. Vol. 98. Numb. 7. North America (C.B-17 SCID mice)
306. Bhatia N., et.al., J Invest Dermatol. 2013 March ; 133(3): 759-767. North America (athymic nude mice)
307. Mischek D., et.al., Journal of Biomedicine and Biotechnology, Volume 2009 (2009), Article ID 437284. Germany (SCID-beige mice)
308. Harrell JC., et.al., Cancer Res September 15, 2006 66; 9308. North America (athymic nude mice)
309. Kumar S., et.al., Am J Pathol. 2003 December; 163(6): 2531-2541. North America (athymic nude mice)
310. Schafer JM., et.al., Clin Cancer Res November 2000 6; 4373. North America (athymic nude mice)
311. Gottardis MM., et.al., J Steroid Biochem. 1988;30(1-6):311-4. North America (athymic nude mice)
312. O’Regan RM., et. al., JNCI J Natl Cancer Inst (2002) 94 (4): 274-283. North America (athymic nude mice)
313. Morrison MM., J Clin Invest. 2013;123(10):4329-4343. North America (athymic nude mice)
314. Suhong Xiao, et.al., The Journal of Biological Chemistry, 287, 12559-12577. North America (athymic nude mice, beige-nude-xid mice, SHrN® mice)
315. Nguyen N, et.al., Cancer Prev Res. February 2011 4; 248. North America (athymic nude mice)
316. Wang S, at.al., Cancer Gene Therapy (2002) 9, 1-8. doi:10.1038/sj.cgt.7700402. North America (athymic nude mice)
317. Mathieu V.et.al, Oncotarget. Apr 2012; 3(4): 399-413. Germany (BALB/c SCID mice)
318. Vaha-Koskela MJV., et.al., Cancer Res July 15, 2006 66; 7185. The Netherlands (SCID mice)
319. Thallinger C., et.al., Journal of Investigative Dermatology (2003) 120, 1081-1086; doi:10.1046/j.1523-1747.2003.12252.x. Germany (C.B-17 SCID mice)
320. Mathieu MG., et.al., Cell Death and Disease (2014) 5, e1061; doi:10.1038/cddis.2014.29 Published online 13 February 2014. United Kingdom (NOD.SCID mice)
321. Hafner C., et.al., Int. J. Cancer: 114, 426-432 (2005). Germany (C.B-17 SCID mice)
322. Luciani F, et.al., Oxford Journals Medicine JNCI J Natl Cancer Inst Volume 96, Issue 22 Pp. 1702-1713. Italy (C.B-17 SCID mice)
323. Ong C.C., et.al., JNCI J Natl Cancer Inst (2013) djt054 doi: 10.1093/jnci/djt054. North America (beige-nude-xid mice)
324. Lotan T., et.al., Cancer Res. Apr 1, 2008; 68(7): 2166-2175. North America (beige-nude-xid mice)
325. Goel A., et.al., Blood 2007 110: 2342-2350. North America (beige-nude-xid mice)
326. Zeng Y, et.al., J Biol Chem. Apr 22, 2011; 286(16): 13985-13994. North America (C.B-17 SCID mice)
327. Hofmann M., et.al., Neoplasia (New York, N.Y.) (Impact Factor: 5.48). 09/2009; 11(8):812-22. Germany (NOD.SCID mice)
328. Wang L., et.al., J Clin Neurosci. Jun 2012; 19 (6): 881-883. North America (NOD.SCID mice)
329. Sharad S. Singhal, et.al., Cancer Res. May 15, 2009; 69(10): 4244-4251. North America (athymic nude mice)
330. Amornphimoltham P., et.al., Clin Cancer Res. Mar 15, 2013; 19(6): 1375-1388. North America (athymic nude mice)
331. Ricci-Vitiani L., et.al., Cell Death and Differentiation (2008) 15, 1491-1498; doi:10.1038/cdd.2008.72; published online 23 May 2008. Italy (athymic nude mice)
332. Chiron M., et.al., Mol Cancer Ther June 2014 13; 1636. France (NMRI nude mice)
333. Presnell SC., et.al., Am J Pathol. Sep 2001; 159(3): 855-860. North America (athymic nude mice)
334. Stebbing J., et.al., Cancer. Volume 120, Issue 13, pages 2006-2015, 1 July 2014. North America (athymic nude mice)
335. Weekes CD., et.al., Neoplasia. Aug 2012; 14(8): 69-701. North America (athymic nude mice)
336. Pitts TM, et al., (2014) PLoS ONE 9(11): e113037. doi:10.1371/journal.pone.0113037. North America (athymic nude mice)
337. Toussaint G.L., et.al., Molecular Cancer 2012, 11:32. North America (athymic nude mice)
338. Bradshaw-Pierce E.L., et.al., Front. Pharmacol., 22 March 2013 | doi: 10.3389/fphar.2013.00022. North America (athymic nude mice)
339. Petit V., et.al., Laboratory Investigation (2013) 93, 611-621; doi:10.1038/labinvest.2013.44; published online 4 March 2013. France (BALB/c nude mice)
340. Anne L van de Ven, et.al., New Journal of Physics 15 (2013) 055004. North America (SCID-beige mice)
341. Tchoghandjian A., et.al., Cell Death & Differentiation 21, 735-747 (May 2014). France (athymic nude mice)
342. Veeravagu A., et.al., Clin Cancer Res November 15, 2008 14; 7330. North America (athymic nude mice)
343. Mei J., et.al., Mol Cell Biol. Sep 2011; 31(7):3584-3592. North America (NOD.SCID mice)
344. Wang J., et al., Cancer Cell 12, 239-251, September 2007. North America (athymic nude mice)
345. Chisholm EJ., et.al., Cancer Res March 15, 2009 69; 2655. United Kingdom (BALB/c nude mice)
346. Gao Z., et.al., International Journal of Cancer Volume 82, Issue 3, pages 346-352, 30 July 1999. North America (athymic nude mice)
347. Dauchy RT., et.al., Comparative Medicine. Vol. 62, No 2, April 2012, pages 99 - 108. North America (athymic nude rats)
348. Diagle SR., et.al., Blood: 122 (6). August 8, 2013. North America (athymic nude rats)
349. Serra V, et.al., J Clin Invest. 2013;123(6):2551-2563. Spain (athymic nude mice, NMRI nude mice)
350. Nephew KP., et. al., Cancer Res Published OnlineFirst July 17, 2014. North America (athymic nude mice)
351. Pirazzoli V., et.al., Cell Reports 7, 999-1008, May 22, 2014. North America (athymic nude mice)
352. Garcia R.R., et.al., Am J Clin Exp Urol 2014;2(1):82-91. North America (athymic nude mice)
353. Nofiele JT., et.al., PLoS ONE 9(5): e97950. North America (athymic nude rats)
354. Kolev, V.N., et al., Cancer Res January 15, 2015 75; 446. North America (SHrN™ mice, NOD.SCID mice)
355. Colletti, JA II et al. G3 (Bethesda). 4 (2014) 1385-1394. North America (Brown Norway rats)
356. Munson, JM., et al. Cancer Res. 73 (2013) 1536-1546. Swtizerland (Fisher 344 rats)
357. Bhattacharya, A., et al. Carcinogenesis. 34 (2013) 2593-2599. North America (Fisher 344 rats)
358. Janakiram, NB., et al., Cancer.Prev.Res.(Phila). 6 (2013) 1251-1261. North America (Fisher 344 rats)
359. Ravillah, D., et al. et al., J.Pharmacol.Exp.Ther. 348 (2014) 59-68. North America (Fischer 344 rats)
360. Shi, N., et al. Oncotarget. 5 (2014) 11333-11344. North America (Fischer 344 rats)
361. Yang, L., et al., Int.J.Biochem.Mol.Biol. 3 (2012) 46-57. China (Fischer 344 rats)
362. Stypula-Cyrus, Y., et al., FEBS Lett. 588 (2014) 829-835. North America (Fischer 344 rats)
363. Khazal, KF., et al. Anticancer Res. 33 (2013) 1519-1523. North America (Spraque Dawley rats)
364. Ouyang, N., et al. Int.J.Oncol. 42 (2013) 643-650. North America (Fischer 344 rats)
365. Ostertang D., et.al., Neuro Oncol. 2012 February; 14(2): 145–159. North America (B6C3F1 mice)
366. Rashid OM., et.al., Journal of Thoracic Disease. Vol 5, No 4 (August 2013). North America (BALB/c mice)
367. Anz, D., et al, Int.J.Cancer 129 (2011) 2417-2426. Germany (C57BL/6 mice; BALB/c mice)
368. Barbieri, A., et al, J.Cell.Mol.Med. 16 (2012) 920-926. Italy (C57BL/6 mice)
369. Adinolfi, E., et al. Cancer Res. 72 (2012) 2957-2969. Italy (C57BL/6 mice; BALB/c mice)
370. Gurzov, EN., et al. Oncogene 27 (2008) 641-652. Spain (C57BL/6 mice)
371. Basile, LA., et al. J.Transl.Med. 6 (2008) 26-5876-6-26. North America (C57BL/6 mice)
372. Balkow, S., et al, Exp.Dermatol. 18 (2009) 78-87. Germany (C57BL/6 mice)
373. Llopiz, D., et al, Int.J.Cancer 125 (2009) 2614-2623. Spain (C57BL/6 mice)
374. Jacobs, C., et al, Int.J.Cancer 128 (2011) 897-907. Germany (C57BL/6 mice)
375. Aranda, F., et al, Cancer Res. 71 (2011) 3214-3224. 2011. Spain (C57BL/6 mice)
376. Li, X., et al, Oncogene 27 (2008) 7118-7130. North America (C57BL/6 mice)
377. Spitzer, D., et al, Cancer Res. 72 (2012) 201-209. North American (C57BL/6 mice)
378. Uluckan, MC., et al, J.Cell.Biochem. 104 (2008) 1311-1323. North American (C57BL/6 mice)
379. Bandyopadhyay, A., et al. PLoS One 5 (2010) e10365. North America (BALB/c mice)
380. Cambien, B., et al, PLoS One 6 (2011) e28842. France (BALB/c mice)
381. Cooney, CA., et al, Breast Cancer Res. 13 (2011) R58. North America (BALB/c mice)
382. Israyelyan, A., et al. Virol.J. 5 (2008) 68-422X-5-68. North America (BALB/c mice)
383. Jungwirth, U., et al. et al, Mol.Pharmacol. 81 (2012) 719-728. Austria (BALB/c mice)
384. Lapteva, N., et al. J.Immunother. 32 (2009) 145-156. North America (BALB/c mice, C57BL/6J mice)
385. Mojic, M., et al. Mol.Pharmacol. 82 (2012) 700-710. Serbia (BALB/c mice)
386. Qiao, Y., et al. Oncotarget 2 (2011) 59-68. North America (BALB/c mice)
387. Vanrell, L., et al, Mol.Ther. 19 (2011) 1245-1253. Spain (BALB/c mice)
388. Vigneswaran, N. et al. Exp.Mol.Pathol. 90 (2011) 215-225. North America (BALB/c mice)
389. Walsh, C., et al, Cancer.Biol.Ther. 9 (2010) 778-790. North America (BALB/c mice)
390. Zhang, M., et al, Cancer Res. 68 (2008) 4674-4682. North America (BALB/c mice)
391. Zigmond, E., et al. PLoS One 6 (2011) e28858. Israel (BALB/c mice)
392. Ganesh, S., et al. Mol Cancer Ther (2016) Jul 7. North America (athymic nude mice)
393. Jiménez-Valerio, G. et al. Cell Rep. (2016) May 10; 15(6):1134-43. Spain (athymic nude mice)
394. Zhao, S., et al., Clin Cancer Res. (2016) Jun 7. North America (athymic nude mice)
395. Francis, DM., et al. Clin Cancer Res. (2016) Feb 1; 22(3):633-43. North America (athymic nude mice)
396. Crottès D., et al. Cancer Res. 2016 Feb 1; 76(3):607-18. France (SHrN™ mice)
397. Kathagen-Buhmann A., et al. Neuro Oncol. 2016 Feb 24. Germany (SHrN™ mice)
398. Jones R.J., et al. Clin Cancer Res. 2016 Jun 13. North America (C.B-17 SCID mice)
399. Alagpulinsa D.A., et al. Mol Cancer Ther. 2016 Feb; 15(2):241-50. North America (C.B-17 SCID mice)
400. Halle B., et al. J Neurooncol. 2016 Jan; 126(1):47-55. Denmark (athymic nude rats)
401. Debeb B.G., et al. J Natl Cancer Inst. 2016 Apr 13; 108(8). North America (SCID-beige mice)
402. Hudson K., et al. Mol Cancer Ther. 2016 May; 15(5):877-89. United Kingdom (SCID-beige mice)
403. Gravekamp, C., et al. (2004). Experimental Biology and Medicine, 229(7), 665-675. North America (BALB/c mice)
404. Toussaint, M., et al. Theranostics, 2017; 7(2): 436-451. France (athymic nude rat)
405. Li, R., et. al, Current Cancer Drug Targets, 2014, 14, 274-285. China (athymic nude mouse)
406. Schoenfeld, J.D., et al. Redox Biol. 2018 Apr;14:417-422. North America (athymic nude mouse)
407. Sciegienka S.J., et al. Free Radic Biol Med. 2017 Jul;108:354-361. North America (athymic nude mouse)
408. Segatto, I., et al. Aging, 8(5), 958-976. United Kingdom (athymic nude mouse)
409. Sen, T., et al. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 2017 23(20), 6239-6253. North America (athymic nude mouse)
410. Shao, C., et al. J Biol Chem. 2015 Jan 23;290(4):2024-33. North America (athymic nude mouse)
411. Stafman, L.L., et al. Oncotarget. 2018 Apr 27; 9(32): 22665–22679. North America (athymic nude mouse)
412. Tan Q., et al. Br J Cancer. 2015 Mar 3; 112(5): 832–840. North America (athymic nude mouse)
413. Toden S., et al. Oncotarget. 2016 Mar 29; 7(13): 16158–16171. North America (athymic nude mouse)
414. Wang W., et al. J Neurosurg. 2018 Mar;128(3):695-700. North America (athymic nude mouse)
415. Waters A.M., et al. Mol Cancer Ther. 2016 May; 15(5): 911–921. North America (athymic nude mouse)
416. Yan H., et al. Oncotarget. 2016 Jul 12; 7(28): 43352–43362. North America (athymic nude mouse)
417. Yan S.B., et al. Invest New Drugs. 2018; 36(4): 536–544. North America (athymic nude mouse)
418. Yeo S.K., et al. Cancer Res. 2016 Jun 1; 76(11): 3397–3410. North America (athymic nude mouse)
419. Zumwalt T.J., et al. Cancer Prev Res (Phila). 2017 Mar; 10(3): 208–218. North America (athymic nude mouse)
420. Alexander M.S., et al. Cancer Res. 2018 Sep 25. pii: canres.1680.2018. North America (athymic nude mouse)
421. Choi A.H., et al. Surgery. 2018 Feb;163(2):336-342. North America (athymic nude mouse)
422. Donabedian P.L., et al. EJNMMI Res. 2018; 8: 59. North America (athymic nude mouse)
423. Nguyen O.N., et al. Cancer Res. 2017 Mar 15;77(6):1427-1438. Europe (BALB/c mice)
424. Barrett, J. A., et al. 2018. Cancer Gene Therapy, 25(5-6), 106-116. North American (C57BL/6 mice)
425. Thisgaard, H., et al. 2016. Theranostics, 6(12), 2278-2291. Denmark (athymic nude rats)
426. Buck, J. R., et al. 2015. PloS One, 10(10), e0141659. North America (athymic nude rats)
427. Gruslova, A., 2015. Journal of Neuro-Oncology, 124(3), 365-372. North America (athymic nude rats)
428. Qureshi-Baig, K., 2016. PloS One, 11(1), e0146052. Europe (NOD.SCID mice)
429. Torres-Guzman, R., et al. 2017. Oncotarget, 8(41), 69493-69507. North America (NOD.SCID mice)
430. Zhang, Y., et al. 2018. Nature Communications, 9(1), 4080-018-06177-2. North America (NOD.SCID mice)
431. Banerjee, K., et al. 2018. Clinical Oncology and Research, 1(1). North America (NOD.SCID mice)
432. Frosina, G., et al. 2018. Scientific Reports, 8(1), 14191-018-32578-w. Europe (NOD.SCID mice)
433. Gross, A. C., et al. 2018. JCI Insight, 3(16), 10.1172/jci.insight.99791. North America (C.B-17 SCID mice)
434. Kryeziu, K., et al. 2016. Oncotarget, 7(19), 27379-27393. Europe (C.B-17 SCID mice)
435. Ryan, M. C., et al. 2017. Blood, 130(18), 2018-2026. North America (C.B-17 SCID mice)
436. Abrams, T., et al. 2018. Clinical Cancer Research, 24(17), 4297-4308. North America (SCID-beige mice)
437. Butler, K. A., et al. 2017. Neoplasia (New York, N.Y.), 19(8), 628-636. North America (SCID-beige mice)
438. Gill, S. E., et al. 2017. Oncotarget, 8(49), 85214-85223. North America (SCID-beige mice)
439. Goncalves, A. F., et al. 2017. Nature Communications, 8(1), 1466-017-01514-3. Europe (SCID-beige mice)
440. Park, J. H., et al. 2016. Cell Reports, 14(9), 2154-2165. North America (SCID-beige mice)
441. Debeb, B. G., et al. 2016. Journal of the National Cancer Institute, 108(8). North America (SCID-beige mice)
442. Song, W., et al. 2017. Oncogene, 36(40), 5620-5630. North America (NOD.SCID mice)
443. Williams, A. P., et al. 2018. Translational Oncology, 12(1), 84-95. North America (athymic nude mouse)
444. Yu, X., et al. 2018. International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, 47(3), 957-971. Asia (athymic nude mouse)
445. Ziegler, J., et al. (2017). Oncotarget, 8(42), 71833-71844. North America (athymic nude mouse)
446. Van de Sande, L., et al. (2019). BMC Cancer, 19(1), 424. Belgium (athymic nude rats)
447. Grünewald, S., et al. (2019). Int J Cancer, 145(5), 1346-1357. Germany (athymic nude rats)
448. Owonikoko, T.K., et al. (2019). PLoS One, 14(2), e0206309. North America (athymic nude rats)
450. Vermandel, M., et al. (2019). Photodiagnosis Photodyn Ther, 25, 166-176. France (athymic nude rats)
451. Vega, F.M., et al. (2019). EBioMedicine, 49, 82-95.Spain (CB-17 mice)
452. Wang, Y., et al. (2019). Mol Cancer Ther, 19(2), 364-374. North America (CB-17 mice)
453. Nguyen, T., et al. (2019). Cell Rep, 27(2), 491-501.e6 North America (CB-17 mice)
454. Pfitzer, L., et al. (2019). Cell Death Dis, 10(4), 302. Germany (CB-17 mice)
455. Fonti, C., et al. (2019). Int J Cancer, 145(5), 1299-1311. France (SCID-beige mice)
456. Felder, M., et al. (2019). Gynecol Oncol, 152(3), 618-628 North America (SCID-beige mice)
457. Torres, D., et al. (2019). PLoS One, 4(11), e0224564. North America (SCID-beige)
458. Santiago-O'Farrill, J.M., et al. (2020). Bast RC Jr. Cancer, 126(4), 894-907. North America (SCID-beige)
459. McDaid, W.J., et al. (2019). Nanoscale, 11(42), 20261-20273. UK (SCID-beige)
460. Kanakkanthara, A., et al. (2019). Nat Commun, 10(1), 4632. North America (SCID-beige)
461. Le Joncour, V., et al. (2019). Mol Cancer Ther, 18(10), 1721-1730. Finland (SCID-beige)
462. Guerra-Rebollo, M., et al. (2019). Sci Rep, 9(1), 9549. Spain (SCID-beige)
463. Owonikoko, T.K., et al. (2019). PLoS One, 14(2), e0206309. North America (SCID-beige)
464. Wang, W., et al. (2019). J Clin Invest, 129(3), 1015-1029. North America (SCID-beige)
465. Assimon, V.A., et al. (2019). ACS Chem Biol, 14(2), 236-244. North America (SCID-beige)
466. Nachliely, M., et al. (2019). J Steroid Biochem Mol Biol, 188, 8-16. Israel (SCID-beige)
467. Harris, F.R., et al. (2019). Mol Oncol, 13(2), 132-152. North America (SCID-beige)
468. Adler-Levy, Y., et al. (2019). Sensors (Basel), 19(9). Israel (SCID-beige)
469. Ramirez, A.B. et al. (2019). BMC Cancer, 19(1), 220. North America (SCID-beige)
470. Schweppe, R.E., et al. (2019). Mol Cancer Res, 17(5), 1036-1048. North America (SCID-beige)
471. Shamai ,Y., et al. (2019). Stem Cells, 37(2), 176-189. Israel (SCID-beige)
472. Vandergaast, R., et al. (2019). Cancer Gene Ther, 27(3-4), 179-188. North America (SCID-beige)
473. Kim, I.S., et al. (2019). Nat Cell Biol, 21(9), 1113-1126. North America (SCID-beige)
474. Cai, D., et al. (2019). Nat Commun, 10(1), 4621. North America (CB-17)
475. Ceresa, D., et al. (2019). Int J Mol Sci, 20(16). Italy (NOD.SCID)
477. Arroyo-Crespo, J.J., et al. (2019). Int J Cancer, 145(8), 2267-2281. Spain (NOD.SCID)
478. Gatta, L.B., et al. (2019). Cancers (Basel), 11(9), pii: E1219. Italy (NOD.SCID)
479. Ghosh, S.,et al., Front Oncol, 9, 17. Israel (NOD.SCID)
480. Kalli, M., et al. (2019). Front Oncol, 9,32. Cyprus (NOD.SCID)
481. Ron, A., et al. (2019). Cancer Res, 79(18), 4767-4775. Germany (NOD.SCID)
482. Santoro, A., et al. (2019). Cell Rep, 26(3), 624-638.e8. Italy (NOD.SCID)
483. Schrama, D., et al. (2019). Int J Cancer, 145(4), 1020-1032. Germany (NOD.SCID)
484. Stafman, L.L., et al. Sci Rep, 9(1), 13259. North America (NOD.SCID)
485. Terrasi, A., et al. (2019). EBioMedicine, 41, 214-224. Italy (NOD.SCID)
486. Woosley, A.N., et al.Oncogene, 38(20), 3794-3811 North America (NOD.SCID)
487. Wu, J. et al. (2019). Nature, 572(7769), 402-406. North America (NOD.SCID)
488. Aasen, S.N., et al. (2019). Int J Mol Sci, 20(17). Norway (NOD.SCID)
489. Amodio, N., et al., (2019). Cancers (Basel), 18, 11(2). pii: E236. Italy (NOD.SCID)
490. Badarni, M., et al. (2019). JCI Insight, 5. pii: 125341. Israel (NOD.SCID)
491. Benguigui M, et al. (2019). Sci Rep, 9(1), 12613. Israel (NOD.SCID)
492. Falah, M., et al. (2019). Int J Mol Sci, 20(19). Israel (NOD.SCID)
493. Feng, Y., etal. (2019). J Exp Clin Cancer Res, 38(1), 54. China (NOD.SCID)
494. Hammer, S., et al. (2020) Clin Cancer Res, 26(8),1985-1996. Germany (NOD.SCID)
495. Hoogi, S., et al. (2019). J Immunother Cancer, 7(1), 243. Israel (NOD.SCID)
496. Krishnamoorthy, G.P., et al. (2019). Cancer Discov, 9(2), 264-281. North America (NOD.SCID)
497. La Rocca, F., et al. (2017). Cell Oncol (Dordr), 40(5), 483-496. Italy (NOD.SCID)
498. Otto, M., et al. (2019). Clin Oral Investig, 23(10), 3767-3775. Germany (NOD.SCID)
499. Punzi, S., et al. (2019). Breast Cancer Res, 21(1), 123. Italy (NOD.SCID)
500. Sharma, S. et al., (2019). EBioMedicine, 44, 194-208. North America (NOD.SCID)
501. Fusciello, M., etal. (2019). Nat Commun, 10(1), 5747. Canada (athymic nude mice)
502. Neiveyans, M., et al. (2019). Mabs, 11(3), 593-605. France (athymic nude mice)
503. Ryu, J.S., et al. (2019). Cancers (Basel), 11(4), pii: E574. Korea (athymic nude mice)
504. Sayyad M.R., et al. (2019). Breast Cancer Res Treat, 178(1), 35-49. North America (athymic nude mice)
505. Schweppe, R.E., et al. (2019). Mol Cancer Res, 17(5), 1036-1048. North America (athymic nude mice)
506. Stafman, L.L., et al. (2019). Transl Oncol, 12(2), 200-208. North America (athymic nude mice)
507. Akla B., et al. (2020). Mol Cancer Ther, 19(1), 168-177. France (athymic nude mice)
508. Assimon, V.A., et al. (2019). ACS Chem Biol, 14(2), 236-244. North America (athymic nude mice)
509. Belli, V., et al. (2019). Exp Clin Cancer Res, 38(1), 236. Italy (athymic nude mice)
510. Capasso, A., et al. (2019). Mol Cancer Ther,18(11), 1916-1925. North America (athymic nude mice)
511. Casagrande N., et al. (2019). Haematologica, 104(3), 564-575. Italy (athymic nude mice)
512. Duo, L., et al. (2019). Nat Commun, 10(1), 5051. China (athymic nude mice)
513. Eskra, J.N., et al. (2019). Prostate, 79(2), 223-233.North America (athymic nude mice)
514. Fok, J.H.L., et al. (2019). Nat Commun, 10(1), 5065. UK (athymic nude mice)
515. Formisano, L., et al. (2019). Nat Commun, 10(1), 1373. North America (athymic nude mice)
516. Hain, B.A., et al. (2019). JCSM Rapid Commun, 2(1), pii: e00075. North America (athymic nude mice)
517. Hegde, G.V., et al. (2019). Elife, 8, pii: e46551. North America (athymic nude mice)
518. Kietzman, W.B., et al. (2019). Mol Cancer Ther, 18(12), 2220-2232. North America (athymic nude mice)
519. Liu, P., et al. (2019). Nat Commun, 10(1), 1486. France (athymic nude mice)
520. Maaland, A.F., et al. (2019). Eur J Nucl Med Mol Imaging, 46(11), 2311-2321. Norway (athymic nude mice)
521. Moon, H.H. et al. (2019). Endocrinology, 160(8), 1786-1796. North America (athymic nude mice)
522. Nguyen, T., et al. (2019). Cell Rep, 27(2), 491-501.e6. North America (athymic nude mice)
523. Rello-Varona, S., et al. (2019). Sci Rep, 9(1), 3816. Spain (athymic nude mice)
524. Williams, A.P., et al. (2019). Transl Oncol, 12(10), 1364-1374. North America (athymic nude mice)
525. Wu, J., et al. (2019). Nature, 572(7769), 402-406. North America (athymic nude mice)
526. Yang, H., et al. (2019). Clin Cancer Res, 25(18), 5702-5716. North America (athymic nude mice)
527. Yang, L., et al. (2019). Sci Transl Med, 11(476). North America (athymic nude mice)
528. Chang, Y.C., et al. (2017). Sci Rep, 7(1), 9746. North America (RAG2 KO(SD))
529. Fisher, C., et al. (2019). J Clin Med, 8(12), pii: E2214. North American (RAG2 KO(SD))
530. Chen, Z.H., et al. (2019). J Exp Clin Cancer Res, 14;38(1), 196. China (B-NDG)
531. Chen, Z., et al. (2019). EBioMedicine, 47, 208-220. China (B-NDG)
532. Dai, K, et al. (2018). Eur J Immunol, 48(4), 683-695. China (B-NDG)
533. Li, Y., et al. (2018). J Exp Clin Cancer Res, 37(1), 276. China (B-NDG)
534. Sun, B., et al. (2019). Cancer Immunol Res, 7(11), 1813-1823. China (B-NDG)
535. Wang, J., et al. (2020). Thorac Cancer. China (B-NDG)
536. Wang, Q., et al. (2018). Clin Cancer Res, 24(4), 950-962. China (B-NDG)
537. Xia, J., et al. (2020). Mol Oncol, 14(4), 763-778. China (B-NDG)
538. Xiao, X., et al. (2017). Cell Death Dis, 8(9), e3050. China (B-NDG)
539. Ao, X., et al. (2019). J Immunother, 42(8), 284-296. China (B-NDG)
540. Chen, H.D., et al. (2020). Int J Biol Sci, 16(7), 1207-1217. China (B-NDG)
541. Gao , X., et al. (2019). Clin Cancer Res, 25(4), 1291-1301. China (B-NDG)
542. Gong, J., et al. (2020). Artif Cells Nanomed Biotechnol, 48(1), 408-414. China (B-NDG)
543. Chen, R., et al. (2020). Cancer Lett. 469, 162-172. China (B-NDG)
544. Huang W., et al. (2020). Cell Death Differ, 27(5), 1709-1727. China (B-NDG)
545. Lei, H., et al. (2019). Cancer Invest, 37(6), 242-252. China (B-NDG)
546. Sun, Y., et al. (2019). EBioMedicine, 43, 171-179. China (B-NDG)
547. Wang, D., et al. (2018). J Cell Mol Med, 22(12), 6202-6212. China (B-NDG)
548. Wu, R., et al. (2019). Pharmacol Res, 150, 104454. China (B-NDG)
549. Xiao, H., et al. (2019). Cancer Cell Int, 19, 218. China (B-NDG)
550. Yang, D. , et al. (2019). J Immunother Cancer, 7(1), 171. China (B-NDG)
551. Zhan, Y., et al. (2020). Mol Cancer, 19(1), 25. China (B-NDG)
552. Zhang, P., et al. (2020). J Biomed Sci, 27(1), 30. China (B-NDG)
553. Zhao, B., et al. (2019). Theranostics, 9(7), 1837-1850. China (B-NDG)
554. Wei, .T et al. (2020).mBio, 11(3):e00908-20. North America (athymic nude mice)
555. Tuominen, S., et al. (2020). Eur. J. Nucl. Med. Mol. Imaging, doi: 10.1007/s00259-020-05115-z. Finland (athymic nude mice)
556. Elwaie, TA., et al. (2020). J Med Chem. 2020 Dec 24;63(24):15906-15945. doi: 10.1021/acs.jmedchem.0c01647. North America (athymic nude mice)
557. Gómez-Aleza, C., et al. (2020). Nat Commun. 11(1):6335. Spain (athymic nude mice)
558. Parsels, LA., et al. (2020). Mol Cancer Ther. doi: 10.1158/1535-7163.MCT-20-0365. North America (athymic nude mice)
559. Gergen, AK., et al. (2020). J Surg Res, S0022-4804(20)30754-X. North America (athymic nude mice)
560. Gadkari, K., et al. (2020). Nutrients, 12(12):3631. North America (athymic nude mice)
561. Wu, Q., et al. (2020). Cell Death Dis, 11(11):1015. China (athymic nude mice)
562. Yi, J., et al. (2020). Proc Natl Acad Sci U S A, 117(49):31189-31197. North America (athymic nude mice)
563. Capone, E., (2020). Cancers (Basel), 12(10):2989. Italy (athymic nude mice)
564. Kim, SI., et al. (2020). Int J Mol Sci, 21(19):7326. North America (athymic nude mice)
565. Bownes, LV., et al. (2021). Transl Oncol,14(1):100893. North America (athymic nude mice)
566. Ridwan, SM., et al. (2020). Nanomedicine (Lond), 15(24):2369-2383. North America (athymic nude mice)
567. Scribner, JA., et al. (2020). Mol Cancer Ther, doi: 10.1158/1535-7163. North America (athymic nude mice)
568. Santich, BH., et al. (2021). Clin Cancer Res, 27(2):532-541. North America (athymic nude mice)
569. Roger, E., et al. (2020) Cells, 9(9):2110. Germany (athymic nude mice)
570. Sun, Y., et al. (2020). Cancer Res, 80(21):4840-4853. North America (athymic nude mice)
571. Dabaghi, M., et al. (2020). Cancers (Basel), 12(9):2562. Germany (athymic nude mice)
572. Ramachandran, S., and Srivasta, S. (2020). Mol Ther Oncolytics, 19:19-32. North America (athymic nude mice)
573. Shibata, M., et al. (2020). Mol Cancer Ther, 19(10):2175-2185. North America (athymic nude mice)
574. Guffanti, F., et al. (2020). Cancers (Basel), 12(9):2398. Italy (athymic nude mice)
575. Gomes, AP., et al. (2020). Nature, 585(7824):283-287. North America (athymic nude mice)
576. Gonzalez-Sanchez, L., et al. (2020). Carcinogenesis, 41(8):1113-1122. Spain (athymic nude mice)
577. Franklin, DA., et al. (2020). JCI Insight, 5(15):e134290. North America (athymic nude mice)
578. England, RM., et. al. (2020). Biomacromolecules, 21(8):3332-3341. UK (athymic nude mice)
579. Gelsomino, L., et al. (2020). Cancers (Basel), 12(8):2078. Italy (athymic nude mice)
580. Nwagwu, CD., et al. (2020). Lab Anim (NY), 49(8):227-232. North America (athymic nude mice)
581. Yan, P., et al, (2020). Cell Rep, 31(13):107840. North America (athymic nude mice)
582. Mohammadabadi, A., et al. (2020). Phys Med Biol, 65(12):125017. North America (athymic nude mice)
583. Chen. Y., et al. (2020). Prostate, 80(12):993-1005. North America (athymic nude mice)
584. Trotta, F., et al. (2020). Mol Cancer Ther, 19(9):1909-1921. Italy (athymic nude mice)
585. Siddique, AB., et al. (2020). Nutrients, 12(6):1749. North America (athymic nude mice)
586. Li, M., et al. (2020). Cancers (Basel),12(6):1538. North America (athymic nude mice)
587. Rossi, SM., et al. (2020). Br J Cancer, 123(3):369-377. Ireland (athymic nude mice)
588. Kennedy, AL., et al. (2020). Cancers (Basel), 12(5):1269. North America (athymic nude mice)
589. Sharick, JT., et al. (2020). Front Oncol, 10:553. North America (athymic nude mice)
590. Schregel, K., et al. (2020). Cancer Imaging, 20(1):35. North America (athymic nude mice)
591. Pattarawat, P., et al. (2020). Br J Cancer, 123(2):226-239. North America (athymic nude mice)
592. Gupta, K., et al. (2020). Front Oncol, 10:535. North America (athymic nude mice)
593. Humeau, J., et al. (2020). EMBO Mol Med. 12(5):e11622. North America (athymic nude mice)
594. Faugeroux, V., et al. (2020). Nat Commun,11(1):1884. North America (athymic nude mice)
595. Fell, JB., et al. (2020). J Med Chem, 63(13):6679-6693. North America (athymic nude mice)
596. Lingasamy, P., et al. (2020). Sci Rep, 10(1):5809. Estonia (athymic nude mice)
597. Tozzi, M., et al. (2020). Cancers (Basel), 12(3):640. Denmark (athymic nude mice)
598. Cam, M., et al. (2020). Neuro Oncol, 22(3):345-356. North America (athymic nude mice)
599. Wang, Y., et al. (2020). J Immunother Cancer. 8(1):e000462. doi: 10.1136/jitc-2019-000462. France (athymic nude mice)
600. Marayati, R., et al. (2020). J Pediatr Surg. 55(6):1072-1080. North America (athymic nude mice)
601. Peddi, S., et al. (2020). Biomacromolecules. 21(3):1091-1102. North America (athymic nude mice)
602. Bousquet Mur, E., et al. (2020). J Clin Invest, 130(2):612-624. France (athymic nude mice)
603. Dwivedi, SKD., et al. (2020). FASEB J. 34(2):2287-2300. North America (athymic nude mice)
604. Bhagwat, SV., et al. (2020). Mol Cancer Ther, 19(2):325-336. North America (athymic nude mice)
605. Sinha, S., et al. (2020). Oncogene, 39(6):1231-1245. North America (athymic nude mice)
606. Somwar, R., et al. (2020). Commun Biol. 23(1):776. North America (athymic nude mice)
607. Domínguez, JM., et al. (2020). J Hematol Oncol. 13(1):32. Spain (athymic nude mice)
608. Zheng, ZY., et al. (2020). Cancer Cell, 37(3):387-402.e7. North America (athymic nude mice)
609. Hammer, S., et al. (2020). Clin Cancer Res, 26(8):1985-1996. Germany (athymic nude mice)
610. Kenny, HA., et al. (2020). Mol Cancer Ther, 19(1):52-62. North America (athymic nude mice)
611. Shen, JZ., Cell, 184(2):352-369.e23. North America (athymic nude mice)
612. Rosenblum, D., et al. (2020). Sci Adv, 6(47):eabc9450. Israel (athymic nude mice)
613. Valle, S., et al. (2020). Nat Commun, 11(1):5265. Spain (athymic nude mice)
614. Alcalá, S., et al. (2020). Int J Mol Sci, 21(20):7437. Spain (athymic nude mice)
615. Zhang, H., et al. (2020). Mol Imaging Biol, 22(5):1184-1196. North America (athymic nude mice)
616. Tiwari, A., et al. (2020). Cancers (Basel), 12(10):2795. Germany (athymic nude mice)
617. Dadwal, UC., et al.. (2020). Int J Mol Sci, 21(18):6913. North America (athymic nude mice)
618. Mansi, R., et al. (2020). Molecules, 25(18):4155. Switzerland (athymic nude mice)
619. Chomet, M., et al. (2020). Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-020-05002-7.
620. Marcazzan, S., et al. (2020). Oral Dis. doi: 10.1111/odi.13592. North America (athymic nude mice)
621. Mansi, R., et al. (2020). EJNMMI Res, 10(1):90. Switzerland (athymic nude mice)
622. Miner, MW., et al. (2020). Mol Imaging Biol, 22(4):969-978. Finland (athymic nude mice)
623. VanOpstall, C., et al. (2020). Elife, 9:e53600. North America (athymic nude mice)
624. Verma, B, Wesa A. Curr Protoc Pharmacol. 89(1):e77. doi: 10.1002/cpph.77. North America (athymic nude mice)
625. Li, M., et al. (2020). Am J Transl Res, 12(5):1862-1872. North America (athymic nude mice)
626. Wei, SJ., et al. (2020). Cell Death Dis, 11(5):368. North America (athymic nude mice)
627. Li, J., et al. (2020). Light Sci Appl. 9:57. doi: 10.1038/s41377-020-0295-y. Germany (athymic nude mice)
628. Fanfone, D., et al. (2020). Biology (Basel), 9(3):53. Belgium (athymic nude mice)
629. Medeiros, B., et al. (2020). Cancers (Basel), 12(1):172. North America (athymic nude mice)
630. Maloney, R., et al. (2020). Methods Enzymol, 638:295-320. North America (athymic nude mice)
631. Shivange, G.,et al. (2020). J Vis Exp, (159). doi: 10.3791/60727. North America (athymic nude mice)
632. Shariati, M., et al. (2020). ACS Appl Mater Interfaces. 12(26):29024-29036. Belgium (athymic nude rats)
633. Chaves, C., et al. (2020). Pharmaceutics. 12(5):399. France (athymic nude mice)
634. Falvo, P., et al. (2020), Cancer Res, Feb 1;81(3):685-697. Italy (BALB/C)
635. Bonavita, E., et al. (2020). Immunity, 53(6):1215-1229.e8. UK (BALB/C)
636. Raineri, D., et al. (2020), Commun Biol, 3(1):615. Italy (BALB/C)
637. Suurs, FV., et al. (2020). EJNMMI Res. 10(1):111. Netherlands (BALB/C)
638. Di Tano, M., et al. (2020), Nat Commun. 11(1):2332. Italy (BALB/C)
639. Teijeira, Á., et al. (2020). Immunity, 52(5):856-871.e8. Spain (BALB/C)
640. Karp, NA., et al. (2020), Sci Rep, 10(1):6178. UK (BALB/C)
641. Kranjc Brezar, S., et al. (2020). Vaccines (Basel), 8(1):135. Slovenia (BALB/C)
642. Li, R., et al. (2020). Mol Cancer Ther 2019;18(12 Suppl):Abstract nr A016. North America (B-NDG)
643. Vigant, F., et al. (2020). Journal for ImmunoTherapy of Cancer; 8:doi: 10.1136/jitc-2020-SITC2020.0117. North America (B-NDG)
644. Pan, LN., et al. (2020). Cell Biol Int, doi: 10.1002/cbin.11524. China (B-NDG)
645. Hu, Z., et al. (2020). Mol Ther Oncolytics, 17:361-370. doi: 10.1016/j.omto.2020.04.008. China (B-NDG)
646. Liu, J., et al. (2020). JCI Insight, 5(12):e134728. doi: 10.1172/jci.insight. North America (B-NDG)
647. Cheng, H., et al. (2020). J Immunol, ;205(6):1497-1502. doi: 10.4049/jimmunol.2000136. China (B-NDG)
648. Lv, C., et al. (2020). Cell Mol Immunol, doi: 10.1038/s41423-020-0429-4. China (B-NDG)
649. Tu, C., et al. (2020). Theranostics, 11(5):2364-2380. doi: 10.7150/thno.47996. China (B-NDG)
650. Guan, L., etl al. (2020), Nan Fang Yi Ke Da Xue Xue Bao. 40(8):1200-1206. China (B-NDG)
651. Hu, XT., et al. (2020). J Exp Clin Cancer Res, 39(1):270. China (B-NDG)
652. Miao, JX., et al. (2020). World J Gastroenterol, 26(32):4802-4816. China (B-NDG)
653. Somwar, R., et al. (2020). Commun Biol, 3(1):776. North America (C.B-17 SCID)
654. Moquist, PN., et al. (2020). Mol Cancer Ther, 20(2):320-328. North America (C.B-17 SCID)
655. Thomas, A., et al. (2020). Cancers (Basel), 12(8):2279. North America (C.B-17 SCID)
656. Jones, RJ., et al. (2020). Front Immunol. 11:1816. North America (C.B-17 SCID)
657. Zhou, W., et al. (2020). Nat Commun, 11(1):3811. North America (C.B-17 SCID)
658. Jin, UH., et al. (2020). Cancers (Basel), 12(8):2097. North America (C.B-17 SCID)
659. McKnight, BN., et al. (2020). Breast Cancer Res, 22(1):37. North America (C.B-17 SCID)
660. Perrone, E., et al. (2020). Front Oncol, 10:118. North America (C.B-17 SCID)
661. Lopez, S., et al. (2020). Oncotarget, 11(5):560-570. North America (C.B-17 SCID)
662. Ghilu, S., et al. (2020). Cancer Chemother Pharmacol, 85(2):251-263. North America (C.B-17 SCID)
663. Han, C., et al. (2020). Gynecol Oncol, 156(2):430-438. North America (C.B-17 SCID)
664. Kang, L., et al. (2020). J Nucl Med, jnumed.120.246595. North America (C.B-17 SCID)
665. Maloney, R., et al. (2020). Methods Enzymol, 638:295-320. North America (C.B-17 SCID)
666. Bilger, A., et al. (2020). Viruses. 12(4):450. North America (athymic nude mice)
667. Liapis, E., et al. (2020). Cancer Res, 80(23):5291-5304. Germany (NOD SCID)
668. Zong, X., et al. (2020). Cancer Res, 80(20):4371-4385. North America (NOD SCID)
669. Solimando, AG., et al. (2020). Haematologica, Apr 30. doi: 10.3324/haematol.2019.239913. North America (NOD SCID)
670. Ronca, R., et al. (2020). Cancer Res, 80(11):2340-2354. Italy (NOD SCID)
671. Hammer, S., et al. (2020). Clin Cancer Res, 26(8):1985-1996. Norway (NOD SCID)
672. Gudlevičienė, Ž., et al. (2020). Medicina (Kaunas), 56(10):547. Lithuania (NOD SCID)
673. Kan, T., et al. (2020). J Immunother Cancer, 8(2):e001010. Israel (NOD SCID)
674. Barilani, M., et al. (2020). EBioMedicine, 57:102848. Italy (NOD SCID)
675. Valta, M., Transl Androl Urol, 9(3):1120-1134. Finland (NOD SCID)
676. Wei, W., et al. (2020). Adv Sci (Weinh), 7(13):1903595. China (R2G2®)
677. Maaland, AF., et al. (2020). PLoS One, 15(3):e0230526. Norway (R2G2®)
678. Chang, G., et al. (2020). Cancer Cell, 38(6):857-871.e7. North America (SCID/Beige)
679. Bartnicka, JJ., et al. (2020). Metallomics, 12(10):1508-1520. UK (SCID/Beige)
680. Gabay, M., et al. (2020). Cell Mol Neurobiol, doi: 10.1007/s10571-020-00969-1. Israel (SCID/Beige)
681. Colon-Otero, G.,et al. (2020). ESMO Open, 5(5):e000926. doi: 10.1136/esmoopen-2020-000926. North America (SCID/Beige)
682. Parhi, L., et al. (2020). Nat Commun, 11(1):3259. doi: 10.1038/s41467-020-16967-2. Israel (SCID/Beige)
683. Reddy, TP., et al. (2020). Breast Cancer Res, 22(1):48. North America (SCID/Beige)
684. De Thaye, E., et al. (2020). Sci Rep, 10(1):6688.  Belgium (SCID/Beige)
685. Zheng, ZY., et al. (2020). Cancer Cell, 37(3):387-402.e7. North America (SCID/Beige)
686. Ronca, R., et al. (2020). Cancer Res, 80(11):2340-2354. Italy (SCID/Beige)
687. Serebrenik, AA., et al. (2020). Clin Cancer Res, 26(13):3397-3407. North America (SCID/Beige)
688. Landolina, N., et al. (2020). Pharmacol Res, 158:104682. doi: 10.1016/j.phrs.2020.104682. Israel (SCID/Beige)
689. Satpathy, S., et al. (2020). Nat Commun.11(1):532. doi: 10.1038/s41467-020-14381-2. North America (SCID/Beige)
690. Santiago-O'Farrill, JM., et al. (2020). Cancer, 126(4):894-907. North America (SCID/Beige)
691. Farrera-Sal, M., et al. (2020). Int J Mol Sci, 21(14):5158. Spain (SCID/Beige)
692. Abou, Diane S., et al. (2021). Journal of Nuclear Medicine 62.12 (2021): 1751-1758. North America (R2G2)
693. Apostolidi, Maria, et al. (2021). Cancer Research 81.16 (2021): 4346-4359. North America (R2G2)
694. Davenport, et al. (2021). Cancer research 81.8 (2021): 1942-1953. North America (R2G2)
695. DeStefanis, RA, et al. (2021): 1944-1944. North America (R2G2)
696. Hoegger, MJ, et al. (2021). Molecular Imaging and Biology 23.5 (2021): 697-702. North America (R2G2)
697. Kakouratos, C., et al. (2021).  British Journal of Cancer 125.10: 1377-1387. Greece (R2G2)
698. Longtine, Met al. (2021): 1500-1500. Journal of Nuclear Medicine. North America (R2G2)
699. Sánchez-Del-Campo, L., (2021). J Exp Clin Cancer Res. Mar 31;40(1):117. doi: 10.1186/s13046-021-01916-8. Spain (R2G2)
700. Qingcong L et al. (2019) Cancer Res 1 July 2019; 79 (13_Supplement): 1052. China (B-NDG b2m)
701. Raitman, I et al. (2021) Blood 138: 2773. North America (B-NDG hIL15)
702. Gergues, M et al. (2021). Blood 138: 2779. North America (B-NDG hIL15)
703. Vézina A, et al. (2021). Mol Cancer Res. 2021 Dec;19(12):2081-2095. doi: 10.1158/1541-7786. North America (athymic rat)
704. Gil-Ranedo J, et al. (2021). Cell Rep. Sep 7;36(10):109673. doi: 10.1016/j.celrep.2021.109673. Spain (athymic rat)
705. Clément, S et al. (2021). NMR in biomedicine vol. 34,6 (2021): e4490. doi:10.1002/nbm.4490. France (athymic rat)
706. Ghomashchi, S et al. (2021). PloS one vol. 16,9 e0256076. doi:10.1371/journal.pone.0256076. North America (athymic rat)
707. Lücking, U et al. (2021). Journal of medicinal chemistry vol. 64,15: 11651-11674. doi:10.1021/acs.jmedchem.1c01000. North America (athymic rat)
708. Mokhtari, R et al. (2021). Cancers vol. 13,11 2784. 3, doi:10.3390/cancers13112784. (athymic rat)
709. Lodestijn, S et al. (2021). Cell reports vol. 37,3: 109852. doi:10.1016/j.celrep.2021.109852. Netherlands (athymic mice)
710. Morales, X et al. (2021). Biomolecules vol. 11,10 1533. doi:10.3390/biom11101533. Spain (athymic mice)
711. Cai, Q. (2021). Science advances. 7,46: eabi6439. doi:10.1126/sciadv.abi6439. North America (CB.17-SCID)
712. Tymon-Rosario, J et al. (2021). Gynecologic oncology 163,2): 334-341. North America (CB.17-SCID)
713. Liu, C et al. (2021). Oncogene vol. 40,35 (2021): 5379-5392. doi:10.1038/s41388-021-01914-2. North America (CB.17-SCID)
714. Wei, J et al. (2021). Cancer research vol. 81,16 (2021): 4275-4289. doi:10.1158/0008-5472.CAN-21-0198 North America (CB.17-SCID)
715. Kendsersky, N et al. (2021). Clinical cancer research. 27,10 (2021): 2938-2946. doi:10.1158/1078-0432.CCR-20-4221. North America (CB.17-SCID)
716. Chandra, V et al.  Cancers vol. 13,10 2322. 12 May. 2021, doi:10.3390/cancers13102322. North America (CB.17-SCID)
717. Unno, K et al. (2021). Cancer research vol. 81,8: 2157-2170. doi:10.1158/0008-5472.CAN-20-3351. North America (CB.17-SCID)
718. Moquist, P et al. (2021). Molecular cancer therapeutics vol. 20,2: 320-328. doi:10.1158/1535-7163.MCT-20-0618. North America (CB.17-SCID)
719. Yeom, D et al. (2021).International journal of molecular sciences 22,1 241. doi:10.3390/ijms22010241. Korea (C.B-17 SCID)
720. Kang L, et al. (2022). Eur J Nucl Med Mol Imaging. ;49(5):1470-1481. doi:10.1007/s00259-021-05593-9. North America (CB.17-SCID)
721. Hoegger, MJ, et al. (2021). Molecular Imaging and Biology 23.5 (2021): 697-702. North America (CB.17-SCID)
722. Novy, Z et al. (2021). Journal of labelled compounds & radiopharmaceuticals vol. 64,7: 262-270. doi:10.1002/jlcr.3909. Czech Republic (CB.17-SCID)
723. Liu, H et al. (2021). Frontiers in oncology vol. 11 692190.doi:10.3389/fonc.2021.692190. North America (CB.17-SCID)
724. Kang, L et al. (2021). Advanced science. 8,10 2001879. doi:10.1002/advs.202001879. North America (CB.17-SCID)
725. Reissig, F et al. (2021). Cancers vol. 13,8 1974. doi:10.3390/cancers13081974. Germany (CB.17-SCID )
726. Sami, E et al. Cancer gene therapy vol. 29,3-4 (2022): 304-325. doi:10.1038/s41417-021-00311-x. North America (CB.17-SCID and athymic mice)
727. Kang, L et al. (2021). Journal of nuclear medicine. 62,3: 372-378. doi:10.2967/jnumed.120.246595. North America (CB.17-SCID)
728. Perrone, F et al. (2021). Journal of controlled release. 330: 1132-1151. doi:10.1016/j.jconrel.2020.11.020. Italy (CB.17-SCID)
729. Schenk, MW et al. (2021). Nature communications.12,1 6652. doi:10.1038/s41467-021-26823-6. UK (SCID/Beige)
730. Hurley, RM et al.  NAR cancer. (2021). 3,3 zcab028. doi:10.1093/narcan/zcab028. North America (SCID/Beige)
731. Wei, J et al. (2021). Cancer research. 81,16 (2021): 4275-4289. doi:10.1158/0008-5472.CAN-21-0198. North America (SCID/Beige)
732. Liu, D et al. (2021).Cell death & disease. 12,8 789. doi:10.1038/s41419-021-04073-0. China (SCID/Beige
733. Potter, DS et al. (2021). Cell death & disease. 12,8 741. doi:10.1038/s41419-021-04029-4. North America (SCID/Beige)
734. Sheng, Q et al. (2021).  Molecular cancer therapeutics. 20,7: 1270-1282. doi:10.1158/1535-7163.MCT-20-0708. North America (SCID/Beige)
735. Sasikumar, PG et al.(2021). Communications biology. 4,1 699. doi:10.1038/s42003-021-02191-1. India (SCID/Beige)
736. Kettler, B et al. (2021). Hepatobiliary & pancreatic diseases international. 20,3 (2021): 279-284. doi:10.1016/j.hbpd.2021.04.005. Germany (SCID/Beige)
737. Veeraraghavan, J et al. (2021). NPJ breast cancer. 7,1 63. doi:10.1038/s41523-021-00274-0. North America (SCID/Beige)
738. Ronca, R et al. (2021). Cancers. 13,9 2255.doi:10.3390/cancers13092255. Italy (SCID/Beige)
739. Bado, IL et al. (2021). Developmental cell. 56,8: 1100-1117.e9. doi:10.1016/j.devcel.2021.03.008. North America (SCID/Beige, athymic nude)
740. Lin, ZP et al. (2021). Scientific reports. 11,1 8042. doi:10.1038/s41598-021-87325-5. North America (SCID/Beige)
741. Shen, T et al. (2021). The Journal of clinical investigation. 131,4: e135465. doi:10.1172/JCI135465. North America (SCID/Beige)
742. Fukumura, K et al. (2021). Acta neuropathologica. 141,2 (2021): 303-321. doi:10.1007/s00401-020-02256-1. North America (SCID/Beige)
743. Gabay, M et al. (2021). Cellular and molecular neurobiology 41,5: 1019-1029. doi:10.1007/s10571-020-00969-1. Israel (SCID/Beige)
744. Iizuka, S et al. (2021). Cancer research vol. 81,6 (2021): 1472-1485. doi:10.1158/0008-5472.CAN-20-2383. North America (SCID/Beige)
745. Smith, DL et al. (2021). Genes & cancer. 12 28-38. doi:10.18632/genesandcancer.212. North America (SCID/Beige)
746. Hu, X et al. (2021).Communications biology. 4,1 72. 15, doi:10.1038/s42003-020-01590-0. North America (SCID/Beige)
747. Fan, F et al. (2021). Leukemia. 35,12: 3509-3525. doi:10.1038/s41375-021-01271-9. Germany (NOD SCID)
748. Castelli, R et al. (2021). European journal of medicinal chemistry. 221: 113529. doi:10.1016/j.ejmech.2021.113529. Italy (NOD SCID)
749. Liapis, E et al. (2021). Theranostics.11,16 7813-7828. doi:10.7150/thno.56173. Germany (NOD SCID)
750. Yajuk, O et al. (2021).Cells. 10,6 1510. doi:10.3390/cells10061510. Israel (NOD SCID)
751. Mensah, A et al. (2021). Blood advances. 5,10: 2467-2480. doi:10.1182/bloodadvances.2020003566. Switzerland (NOD SCID)
752. Ronca, R et al. (2021). Cancers. 13,9 2255.doi:10.3390/cancers13092255. Italy (NOD SCID)
753. Zhang, X et al. (2021). Cancers. 3,7 1672. 1 Apr. 2021, doi:10.3390/cancers13071672. North America (NOD SCID)
754. Grillo, E et al. (2021).Cancer letters. 496: 84-92. doi:10.1016/j.canlet.2020.09.027. Italy (NOD SCID)
755. Urbano, N et al. (2021). Journal of clinical medicine. 10,21 4850. doi:10.3390/jcm10214850. Italy (NOD SCID)
756. O'Kelly, Devin et al. (2021). Scientific reports. 11,1 19872.doi:10.1038/s41598-021-97726-1. North America (NOD SCID)
757. Jayaram, DR et al. (2021). PNAS. 118,40: e2018899118. doi:10.1073/pnas.2018899118. Israel (NOD SCID)
758. Appolloni, I et al. (2021). Viruses. 13,9 1677. doi:10.3390/v13091677. Italy (NOD SCID)
759. Castillo-Ecija, H et al. (2021). The journal of pathology. Clinical research. 7,4: 338-349. doi:10.1002/cjp2.210. Spain (NOD SCID, athymic nude)
760. Solimando, AG et al. (2021). Haematologica.106,7 1943-1956. 1 Jul. 2021, doi:10.3324/haematol.2019.239913. Italy (NOD SCID)
761. Ghosh, M et al. (2021). Cancer cell. 39,4: 494-508.e5. doi:10.1016/j.ccell.2021.01.003. North America (NOD SCID)
762. Marayati, R et al. (2021). Scientific reports. 11,1 5984. doi:10.1038/s41598-021-85289-0. North America (NOD SCID)
763. Bownes, LV et al. (2021). PloS one. 16,3 e0246244. doi:10.1371/journal.pone.0246244. North America (NOD SCID)
764. Marcheteau E, et al. (2021). Cancers (Basel). 13(16):4059. doi:10.3390/cancers13164059. France (BALB/C)
765. Baram T et al. (2021). Cells.10(6):1429. doi:10.3390/cells10061429. Israel (BALB/C)
766. Suurs, FV et al. (2021). Journal of nuclear medicine. 62,12 1797–1804. doi:10.2967/jnumed.120.259036. Netherlands (BALB/C)
767. Petruk, N et al. (2021). Scientific reports. 11,1 6035. doi:10.1038/s41598-021-85379-z. Finland (BALB/C)
768. Ursic K et al. (2021). J Control Release. 2021 Apr 10;332:623-635. doi: 10.1016/j.jconrel.2021.03.009. Slovenia (BALB/C)
769. Falvo, P et al. (2021). Cancer research. 81,3: 685-697. doi:10.1158/0008-5472.CAN-20-1818. Italy (BALB/C)
770. Nie, P et al. (2021). Clinical cancer research. 27,22 : 6145-6155. doi:10.1158/1078-0432.CCR-21-0940. North America (BALB/C)
771. Maulhardt, Holly et al. (2021). Medical oncology. 38,9 106. doi:10.1007/s12032-021-01555-1. North America (BALB/C)
772. Wedekind, MF et al. (2021). iScience. 24,7 102759. doi:10.1016/j.isci.2021.102759. UK (BALB/C)
773. Jang, SC et al. (2021). Communications biology. 4,1 497. doi:10.1038/s42003-021-02004-5. North America (BALB/C)
774. Muleki-Seya, P and O'Brien WD. (2022). IEEE transactions on ultrasonics, ferroelectrics, and frequency control. 69,2: 637-649. doi:10.1109/TUFFC.2021.3130682. North America (F344 rats)
775. Cai, W et al. (2021). Antibody Therapeutics. 4,4 228-241. North America (B-NDG)
776. Cao, Z et al. (2021). Science advances. 7,14 eabf4148. doi:10.1126/sciadv.abf4148. China (B-NDG)
777. Chen, T et al. (2021). Journal for immunotherapy of cancer. 9,1: e001647. doi:10.1136/jitc-2020-001647. China (B-NDG)
778. Chen, Z et al. (2021). American journal of cancer research. 11,1 277-296. China (B-NDG)
779. Gu, Y et al. (2021). Molecular cancer. 20,1 132. 14. doi:10.1186/s12943-021-01435-2. China (B-NDG)
780. Han, Set al. (2021). Frontiers in molecular biosciences. 8 743013. doi:10.3389/fmolb.2021.743013. China (B-NDG)
781. He, H et al. (2021).Journal for immunotherapy of cancer. 9,10 (2021): e002755. doi:10.1136/jitc-2021-002755. China (B-NDG)
782. He, Y et al.  Journal of Cancer vol. 12,20 6198-6208. doi:10.7150/jca.61602. China (B-NDG)
783. Jiang, D et al. (2021). Cancer science. 112,9 (2021): 3585-3597. doi:10.1111/cas.15055. China (B-NDG)
784. Jiang, D et al. (2021). OncoTargets and therapy. 14 4061-4075. doi:10.2147/OTT.S312249. China (B-NDG)
785. Lei, H et al. (2021).Nature communications.12,1 51.doi:10.1038/s41467-020-20259-0.China (B-NDG)
786. Li, G et al. (2021).Cancer cell international. 21,1 223. doi:10.1186/s12935-021-01923-x. China (B-NDG)
787. Li, Y et al. (2021). Journal of hematology & oncology.14,1 100. doi:10.1186/s13045-021-01112-3. China (B-NDG)
788. Mahati, S et al. (2021). Frontiers in molecular biosciences. 8 738219. doi:10.3389/fmolb.2021.738219. China (B-NDG)
789. Mei, H et al. (2021). Journal of hematology & oncology vol. 14,1 161.doi:10.1186/s13045-021-01170-7.China (B-NDG)
790. Qiao, T et al. (2021). Frontiers in oncology. 11 632364. doi:10.3389/fonc.2021.632364. China (B-NDG)
791. Qiao, X et al. (2021).Blood cancer journal. 11,6 111.doi:10.1038/s41408-021-00502-7. China (B-NDG)
792. Wang, S et al. (2021). Molecular therapy. S1525-0016(21)00574-8. doi:10.1016/j.ymthe.2021.11.003. China (B-NDG)
793. Wang, Ying et al. (2021). Cytotherap. 23,8: 715-723. doi:10.1016/j.jcyt.2021.02.117. China (B-NDG)
794. Wei, G et al. (2021). Cell metabolism. 33,10: 2021-2039.e8. doi:10.1016/j.cmet.2021.08.012. China (B-NDG)
795. Xiong, Y et al. (2021).Cell death & disease vol. 12,4 352. doi:10.1038/s41419-021-03606-x. China (B-NDG)
796. Xu, J et al. (2021). Frontiers in oncology. 11 694331. doi:10.3389/fonc.2021.694331.China (B-NDG)
797. Yang, P et al. (2021). Cellular immunology. 360: 104262. doi:10.1016/j.cellimm.2020.104262.China (B-NDG)
798. Yang, Z et al. Nature communications.12,1 4852. doi:10.1038/s41467-021-25032-5. China (B-NDG)
799. Zhang, D et al. (2021). Cell death & disease.12,5 495.doi:10.1038/s41419-021-03748-y. China (B-NDG)
800. Zhang, Y et al. (2021). Molecular cancer therapeutics. 20,11: 2302-2313. doi:10.1158/1535-7163.MCT-21-0203. China (B-NDG)
801. Zhong, W et al. (2021). Blood. 139,7 (2022): 1052-1065. doi:10.1182/blood.2021013579. China (B-NDG)
802. Zhou, C et al. (2021). Molecular therap. 29,4: 1512-1528. doi:10.1016/j.ymthe.2020.12.034. China (B-NDG)
803. Amit C et al. (2021). Abstract LB067: Development of a novel bispecific antibody targeting PD-L1 and CD55 for cancer therapy. China (B-NDG)
804. Yuxin T et al. (2021). Blood (2021) 138 (Supplement 1): 2171.China (B-NDG).
805. Quixabeira, D et al. Frontiers in immunology.12 674400. doi:10.3389/fimmu.2021.674400. Finladn (AURA)
806. Phillips, LM et al. (2021). Neuro-oncology. 23,11: 1911-1921. doi:10.1093/neuonc/noab128. North America (AURA)
807. Douguet, L et al. (2021). Nature communications vol. 12,1 653. doi:10.1038/s41467-021-20912-2. France (C57BL/6)
808. Luna Rl et al. (2021). Pharmacology research & perspectives. 9,5: e00854. doi:10.1002/prp2.854. France (C57BL/6)
809. Cervera-Carrascon, V et al. (2021).Frontiers in immunology vol. 12 706517. doi:10.3389/fimmu.2021.706517. Finland (C57BL/6)
810. Gorka, J et al. (2021). Oncogene. 40,50: 6720-6735. doi:10.1038/s41388-021-02062-3. Poland (athymic mice)
811. O'Kelly, D et al. (2021). Scientific reports . 11,1 19872. doi:10.1038/s41598-021-97726-1. North America (athymic mice)
812. Roy, J et al. (2021). Molecular imaging and biology. 23,5: 745-755. doi:10.1007/s11307-021-01605-0. North America (athymic mice)
813. Merckx, Get al. (2021). Stem cell reviews and reports. 17,5: 1619-1634. doi:10.1007/s12015-021-10159-1. Belgium (Athymic mice)
814. Zhang, M et al. (2021). Bioconjugate chemistry. 32,9 (2021): 2108-2116. doi:10.1021/acs.bioconjchem.1c00392. Singapore (athymic mice)
815. Kampel, L et al. (2021). Journal of controlled release. 337 (2021): 378-389. doi:10.1016/j.jconrel.2021.07.034. Israel (athymic mice)
816. Park, J et al. (2021). Breast cancer research and treatment. 189,2: 333-345. doi:10.1007/s10549-021-06316-2. North America (athymic mice)
817. Walsh, JJ et al. (2021). Frontiers in oncology. 11 692650. doi:10.3389/fonc.2021.692650. North America (athymic mice)
818. Bolaender, A et al. (2021). Nature communications. 12,1 4669. doi:10.1038/s41467-021-24821-2. North America (athymic mice)
819. Kandimalla, R et al. (2021). Cancers. 13,15 3700. 23 Jul. 2021, doi:10.3390/cancers13153700. North America (athymic mice)
820. Li, M et al. (2021). Cancers. 13,15 3676. doi:10.3390/cancers13153676. North America (athymic mice)
821. Benítez, S et al. (2021). Developmental cell. 56,12: 1727-1741.e7. doi:10.1016/j.devcel.2021.04.022. Spain (athymic mice)
822. Chomet, M et al. (2021). EJNMMI research. 11,1 57. doi:10.1186/s13550-021-00799-2. Netherlands (athymic mice)
823. Thomson, CS et al. (2021).Oncogene. 40,24 (2021): 4229-4241. doi:10.1038/s41388-021-01773-x. North America (athymic mice)
824. Tuominen, S et al. (2021). European journal of nuclear medicine and molecular imaging. 48,5: 1312-1326. doi:10.1007/s00259-020-05115-z. Finland (athymic mice)
825. Ferrauto, G et al. (2021). Investigative radiology. 56,5: 301-312. doi:10.1097/RLI.0000000000000742. Italy (athymic mice)
826. Ferreira, CA et al. (2021). American journal of cancer research. 11,4 1586-1599. China (athymic nude)
827. Metwally, K et al. (2021). Biomedical optics express. 12,4 2264-2279. 23 Mar. 2021, doi:10.1364/BOE.419412. France (athymic nude)
828. Schaff, DL et al. (2021). Cancer research. 81,7: 1853-1867. doi:10.1158/0008-5472.CAN-20-1036. North America (athymic mice)
829. Marcazzan, S et al. (2021). Oral diseases. 27,3: 494-505. doi:10.1111/odi.13592. Italy (athymic mice)
830. Gaonkar, RH et al. (2021). Pharmaceuticals (Basel, Switzerland). 14,4 300. doi:10.3390/ph14040300. Poland (athymic mice)
831. Trotta, AMaria et al. (2021). Journal of medicinal chemistry. 64,6: 3449-3461. doi:10.1021/acs.jmedchem.1c00066. Italy (athymic mice)
832. Eyme, KM et al. (2021). STAR protocols. 2,1 100290. doi:10.1016/j.xpro.2020.100290. North America (athymic mice)
833. Chiou, AE et al. (2021). Science advances vol. 7,12 eabf2283. doi:10.1126/sciadv.abf2283. Germany (athymic mice)
834. Li, T et al. (2021). Nature communications. 12,1 1055. doi:10.1038/s41467-021-21206-3. North America (athymic mice)
835. Lanigan, LG et al. (2021). The American journal of pathology. 191,2 (2021): 335-352. doi:10.1016/j.ajpath.2020.10.014. North America (athymic mice)
836. Baschnagel, AM et al. (2021). Scientific reports. 11,1 2520. 28 Jan. 2021, doi:10.1038/s41598-021-81832-1. North America (athymic mice)
837. Shen, JZ et al. (2021). Cell vol. 184,2: 352-369.e23. doi:10.1016/j.cell.2020.11.042. North America (athymic mice)
838. Marayati, R et al. Translational oncology. 14,1: 100893. doi:10.1016/j.tranon.2020.100893. North America (athymic mice)
839. Lingasamy, P et al. (2021). Current cancer drug targets. 21,1: 70-79. doi:10.2174/1568009620666201001112749. Estonia (athymic mice)
840. Shivange, G et al. (2021). Cell reports vol. 37,5: 109953. doi:10.1016/j.celrep.2021.109953. North America (athymic mice)
841. Smith, BD et al. (2021). Molecular cancer therapeutics vol. 20,11: 2098-2109. doi:10.1158/1535-7163.MCT-21-0361. North America (athymic mice)
842. Pandey, S et al. (2021). Molecular oncology vol. 15,11: 3037-3061. doi:10.1002/1878-0261.12959. Germany (athymic mice)
843. Leal, AS et al. (2021). Cancers. 13,19 5004.doi:10.3390/cancers13195004. North America (athymic mice)
844. Sánchez-Guixé, M et al. (2021). Clinical cancer research. 28,1: 137-149. doi:10.1158/1078-0432.CCR-21-1810. Spain (athymic mice)
845. Patel, N et al. (2021). International journal of pharmaceutics. 607: 120943. doi:10.1016/j.ijpharm.2021.120943. North America (athymic mice)
846. Zalles, M et al. (2021). Neuro-oncology advances. 3,1 vdab132. doi:10.1093/noajnl/vdab132. North America (athymic mice)
847. Gozgit, JM et al. (2021). Cancer cell. 39,9: 1214-1226.e10. doi:10.1016/j.ccell.2021.06.018. North America (athymic mice)
848. Pattarawat, P et al. (2021). Cancer chemotherapy and pharmacology. 88,3: 415-425. doi:10.1007/s00280-021-04298-y.North America (athymic mice)
849. Petreus, T et al. (2021). Communications biology vol. 4,1 1001. doi:10.1038/s42003-021-02526-y. UK (athymic mice)
850. Smith, RA et al. (2021). Molecular cancer therapeutics vol. 20,8: 1327-1337. doi:10.1158/1535-7163.MCT-20-0565. North America (athymic mice)
851. Servetto, A et al. (2021). Clinical cancer research. 27,15 (2021): 4379-4396. doi:10.1158/1078-0432.CCR-20-3905. North America (athymic mice)
852. Li, M et al. (2021). European journal of nuclear medicine and molecular imaging. 48,9: 2737-2748. doi:10.1007/s00259-021-05216-3. North America (athymic mice)
853. Kandimalla, R et al. (2021). Cancers. 13,15 3700. 23 Jul. 2021, doi:10.3390/cancers13153700. North America (athymic mice). North America (athymic mice)
854. Lu, J et al. (2021). Cancer research. 81,14: 3905-3915. doi:10.1158/0008-5472.CAN-21-0033.North America (athymic mice)
855. Puigdelloses, M et al. (2021). Journal for immunotherapy of cancer. 9,7: e002644. doi:10.1136/jitc-2021-002644. Spain (athymic mice)
856. Gonzalvez, F et al. (2021). Cancer discovery. 11,7: 1672-1687. doi:10.1158/2159-8290.CD-20-1683. North America (athymic mice)
857. Zhou, Q et al. Cancer research. 81,12: 3333-3346. doi:10.1158/0008-5472.CAN-20-2960. North America (athymic mice)
858. Gayle, S et al. (2021). NAR cancer. 3,2 zcab021. doi:10.1093/narcan/zcab021. North America (athymic mice)
859. Ben-Eltriki, M et al. (2021). Medicines. 8,6 28. doi:10.3390/medicines8060028. North America (athymic mice)
860. Jiménez-Mora, E et al. (2021). International journal of molecular sciences. 22,11 6033.doi:10.3390/ijms22116033. Spain (athymic mice)
861. Crotty, EE et al. (2021). Journal of neuro-oncology. 153,2: 225-237. doi:10.1007/s11060-021-03767-x. North America (athymic mice)
862. Berk, C et al. (2021). Nucleic acid therapeutics vol. 31,3: 237-244. doi:10.1089/nat.2020.0852. Switzerland (athymic mice)
863. Veeraraghavan, J et al. (2021). NPJ breast cancer vol. 7,1 63. doi:10.1038/s41523-021-00274-0. North America (athymic mice)
864. Punturi, NB et al. (2021). Nature communications vol. 12,1 2940.doi:10.1038/s41467-021-23271-0. North America (athymic mice)
865. Li, X et al. (2021). Theranostics vol. 11,14 6873-6890. doi:10.7150/thno.49235. North America (athymic mice)
866. Hasgur, S et al. (2021). Cytotherapy vol. 23,5: 411-422. doi:10.1016/j.jcyt.2020.04.102. North America (athymic mice)
867. Soukupová, J et al. (2021). Molecular cancer therapeutics. 20,5: 775-786. doi:10.1158/1535-7163.MCT-20-0283. UK (Athymic mice)
868. Wang, X et al. (2021). Clinical cancer research. 27,9: 2648-2662. doi:10.1158/1078-0432.CCR-20-2961. North America (athymic mice)
869. Zhang, W et al. (2021). Cell vol. 184,9: 2471-2486.e20. doi:10.1016/j.cell.2021.03.011. North America (athymic mice)
870. Sharvit, L et al. (2021). Cancers vol. 13,9 2017. doi:10.3390/cancers13092017. Israel (athymic mice)
871. Nordmaj, MA et al. (2021). Cell death & disease. 12,4 353.doi:10.1038/s41419-021-03611-0. Denmark (athymic mice)
872. Laakso, H et al. (2021). NMR in biomedicine. 34,4: e4483. doi:10.1002/nbm.4483. Finland (athymic mice)
873. Gergen, AK et al. (2021). The Journal of surgical research. 260: 436-447. doi:10.1016/j.jss.2020.11.016. North America (athymic mice)
874. Marín-Jiménez, JA et al. (2021). Frontiers in immunology. 12 607282. doi:10.3389/fimmu.2021.607282. North America (athymic mice)
875. Kottke, T et al. (2021). Nature communications. 12,1 1930. doi:10.1038/s41467-021-22115-1. UK (athymic mice)
876. Kapoor, S et al. (2021). Cancers. 13,6 1438. 22 Mar. 2021, doi:10.3390/cancers13061438. North America (athymic mice)
877. Imig, JD et al.International journal of molecular sciences vol. 22,6 2793. doi:10.3390/ijms22062793. North America (athymic mice)
878. Kalev, P et al. (2021). Cancer cell vol. 39,2: 209-224.e11. doi:10.1016/j.ccell.2020.12.010. North America (athymic mice)
879. Parsels, L A et al. (2021). Molecular cancer therapeutics vol. 20,2: 263-273. doi:10.1158/1535-7163.MCT-20-0365. North America (athymic mice)
880. Dela Cruz Chuh, J et al. “(2021). mAbs vol. 13,1: 1862452. doi:10.1080/19420862.2020.1862452. North America (athymic mice)
881. Fritsch, C et al. (2021). Molecular cancer therapeutics vol. 13,5: 1117-29. doi:10.1158/1535-7163.MCT-13-0865. Switzerland (athymic mice)
882. Siddique, HR et al.(2021). International journal of cancer vol. 131,7: 1720-31. doi:10.1002/ijc.274009. North America (athymic mice)
883. Di Pompo, G et al. (2021). Frontiers in cell and developmental biology vol. 9 678532. doi:10.3389/fcell.2021.678532. Italy (athymic mice)
884. Andleeb, F et al. (2021). Lasers in surgery and medicine vol. 53,10: 1386-1394. doi:10.1002/lsm.23446. North America (athymic mice)
885. Domenici, G et al.(2021). Cancers vol. 13,4 879. doi:10.3390/cancers13040879. Spain (athymic mice)
886. Pesini, C. et al. (2022). Oncoimmunology. 2022 Jul 6;11(1):2096359. doi: 10.1080/2162402X.2022.2096359. Spain (B-NDG)
887. Di Francesco et al. (2022). Pharmacol Res . 2022 Dec 28;188:106639. doi: 10.1016/j.phrs.2022.106639. Italy (athymic mice)
888. Kalvala et al. (2022). Biochimie. 2022 Dec 17;208:19-30. doi: 10.1016/j.biochi.2022.12.008. North American (athymic mice)
889. Huhtaniemi et al. (2022). iScience. 2022 Apr 25;25(5):104287. doi: 10.1016/j.isci.2022.104287. Finland (athymic mice)
890. Baldini et al. (2022). Int J Mol Sci. 2022 Mar 28;23(7):3724. doi: 10.3390/ijms23073724. Italy (athymic mice)
891. Roshini et al. (2022). Front Oncol. 2022 Oct 11;12:1014749. doi: 10.3389/fonc.2022.1014749. North American (athymic mice)
892. Sebastiani et al. (2022). Eur J Med Chem. 2023 Jan 15;246:114997. doi: 10.1016/j.ejmech.2022.114997. Italy (NOD SCID)
893. Peuhu et al. (2022) Dev Cell. 2022 Oct 24;57(20):2350-2364.e7. doi: 10.1016/j.devcel.2022.09.016. Finland (NOD SCID)
894. Kim et al. (2022). Mol Cancer Res. 2022 Aug 5;20(8):1284-1294. doi: 10.1158/1541-7786.MCR-21-0905. North American (NOD SCID)
895. Zaffran et al. (2022). Cancer Gene Ther. 2022 Nov;29(11):1676-1685. doi: 10.1038/s41417-022-00486-x. Israel (SCID/Beige)
896. Villodre et al. (2022). J Natl Cancer Inst. 2022 Apr 11;114(4):579-591. doi: 10.1093/jnci/djab222. North America (SCID/Beige)
897. Howley et al. (2022). Oncogene 41, 1679–1690 (2022). https://doi.org/10.1038/s41388-022-02199-9. North America (NOD SCID)
898. Quinn et al. (2022). Cancers 2022, 14(3), 762; https://doi.org/10.3390/cancers14030762. North American (NOD SCID)
899. Zhang et al. (2022). J Clin Invest. 2022 May 16;132(10):e151591. doi: 10.1172/JCI151591. North America (athymic mice)
900. Kang et al. (2022). Cell Rep. 2022 Dec 13;41(11):111827. doi: 10.1016/j.celrep.2022.111827. North America (athymic mice)
901. Sharp et al. (2022). Adv Healthc Mater. 2023 Jan;12(3):e2201968. doi: 10.1002/adhm.202201968. UK (athymic mice)
902. Lee et al. (2022). Cells. 2022 Jan 5;11(1):176. doi: 10.3390/cells11010176. North America (athymic mice)
903. Li et al. (2022). Pharmacol Res. 2022 Sep;183:106395. doi: 10.1016/j.phrs.2022.106395. North American (athymic mice)
904. Diamond et al. (2022). Mol Cancer Ther. 2022 Mar 1;21(3):397-406. doi: 10.1158/1535-7163.MCT-21-0455. North America (athymic mice)
905. Jadvar et al. (2022). Acad Radiol. 2022 Sep 29;S1076-6332(22)00496-2. doi: 10.1016/j.acra.2022.09.005. North America (athymic mice)
906. Zhao et al. (2022). Carcinogenesis, Volume 43, Issue 3, March 2022, Pages 217–230, https://doi.org/10.1093/carcin/bgac008. North America (athymic mice)
907. Diéguez-Martínez et al. (2022). Cell Mol Life Sci. 2022 Sep 19;79(10):524. doi: 10.1007/s00018-022-04541-6. Spain (athymic mice)
908. Slater et al. (2023). Front Med (Lausanne). 2023 Jan 9;9:1036322. doi: 10.3389/fmed.2022.1036322. UK (athymic mice)
909. Kuznik et al. (2022). iScience. 2022 Mar 31;25(5):104175. doi: 10.1016/j.isci.2022.104175. Germany (athymic mice)
910. Taffoni et al. (2022). EMBO J. 2022 Dec 27;e111961. doi: 10.15252/embj.2022111961. France (athymic mice)
911. Lainscek et al. (2022). Nat Commun. 2022 Jun 23;13(1):3604. doi: 10.1038/s41467-022-31386-1. Slovenia (CB.17-SCID)
912. Wang et al. (2022). Nat Commun. 2022 Jan 11;13(1):245. doi: 10.1038/s41467-021-27921-1. North America (SCID-beige)
913. Spriano et al. (2022). EJHaem. 2022 Jul 27;3(3):764-774. doi: 10.1002/jha2.535. Switzerland (NOD SCID)
914. Jackson et al. (2022). iScience. 2022 Jul 19;25(8):104787. doi: 10.1016/j.isci.2022.104787. UK (NOD SCID)
915. Kakarla et al. (2022). Cancers (Basel). 2022 May 9;14(9):2336. doi: 10.3390/cancers14092336. North America (CB.17.SCID)
916. Ning et al. (2022). Commun Med (Lond). 2022 Sep 21;2:118. doi: 10.1038/s43856-022-00182-9. North America (CB.17.SCID)
917. Liu et al. (2022). Nat Cancer. 2022 Jul;3(7):866-884. doi: 10.1038/s43018-022-00389-8. North America (CB.17.SCID)
918. Budzik et al. (2022). Cancer Gene Ther. 2022 Aug;29(8-9):1240-1251. doi: 10.1038/s41417-022-00431-y. North America (CB.17.SCID)
919. Vezina et al. (2021). Mol Cancer Res. 2021 Dec;19(12):2081-2095. doi: 10.1158/1541-7786.MCR-19-0995. North America (athymic rat)
920. Clement et al. (2022). Cancer Imaging. 2022 Mar 18;22(1):16. doi: 10.1186/s40644-022-00454-6. France (athymic rat)
921. Andreu et al. (2022). Brain Res. 2022 Sep 15;1791:148002. doi: 10.1016/j.brainres.2022.148002 North America (athymic rat)
922. Chevaleyre et al. (2022). Int J Mol Sci. 2022 Oct 18;23(20):12476. doi: 10.3390/ijms232012476. France (athymic rat)
923. Feola et al. (2022). Elife. 2022 Mar 22;11:e71156. doi: 10.7554/eLife.71156. Italy (Balb/c)
924. Gomes et al. (2022). Nat Metab. 2022 Apr;4(4):435-443. doi: 10.1038/s42255-022-00553-5. North America (Balb/c)
925. Benguigui et al. (2022). Front Immunol. 2022 Jul 7;13:903591. doi: 10.3389/fimmu.2022.903591. Israel (Balb/c)
926. Kol et al. (2022). J Immunother Cancer. 2022 Dec;10(12):e004877. doi: 10.1136/jitc-2022-004877. Netherlands (Balb/c)
927. Hezkiy et al. (2022). Cells. 2022 Nov 18;11(22):3671. doi: 10.3390/cells11223671. Israel (Balb/c)
928. Gutwillig et al. (2022). Elife. 2022 Sep 20;11:e80315. doi: 10.7554/eLife.80315. Israel (C57BL/6)
929. Hangiu et al. (2022). iScience. 2022 Aug 17;25(9):104958. doi: 10.1016/j.isci.2022.104958. Spain (Balb/c)
930. van Beijnum et al. (2022). Nat Commun. 2022 May 23;13(1):2842. doi: 10.1038/s41467-022-30063-7. Netherlands (Balb/c)
931. Alsaid et al. (2022). Mol Imaging Biol. 2022 Oct 20. doi: 10.1007/s11307-022-01781-7. North America (Balb/c)
932. Huang et al. (2022). ACS Biomater Sci Eng. 2022 Dec 12;8(12):5199-5209. doi: 10.1021/acsbiomaterials.2c00966. North America (Balb/c)
933. Meraviglia-Crivelli et al. (2022). Mol Cancer. 2022 Nov 28;21(1):211. doi: 10.1186/s12943-022-01679-6. Spain (C57BL/6)
934. Berger et al. (2022). Proc Natl Acad Sci U S A. 2022 Jul 12;119(28):e2111003119. doi: 10.1073/pnas.2111003119. North America (C57BL/6)
935. Freeling et al. (2022). Cell Death Discov. 2022 Mar 28;8(1):135. doi: 10.1038/s41420-022-00936-3. North America (athymic mice)
936. Salvatori et al. (2022). Neoantigen cancer vaccine augments anti-CTLA-4 efficacy. NPJ Vaccines. 2022 Feb 2;7(1):15. doi: 10.1038/s41541-022-00433-9. Italy (C57BL/6)
937. Koch et al. (2022). J Immunother Cancer. 2022 Jan;10(1):e003368. doi: 10.1136/jitc-2021-003368. North America (C57BL/6)
938. Sheinboim et al. (2022). Cancer Res. 2022 Nov 15;82(22):4164-4178. doi: 10.1158/0008-5472.CAN-22-0237. Israel (C57BL/6)
939. Kudling et al. (2022). Oncoimmunology. 2022 Jul 12;11(1):2096572. doi: 10.1080/2162402X.2022.2096572. Finland (AURA)
940. Marayati et al. (2022). Cancer Gene Ther. 2022 May;29(5):558-572. doi: 10.1038/s41417-021-00334-4. North America (athymic mice)
941. Dang et al. (2022). Cells. 2022 Apr 28;11(9):1481. doi: 10.3390/cells11091481. North America (athymic mice)
942. Remsik et al. (2022). Cancer Rep (Hoboken). 2022 Apr;5(4):e1236. doi: 10.1002/cnr2.1236. North America (athymic mice)
943. Pradhan et al. (2022). Front Oncol. 2022 Mar 24;12:812560. doi: 10.3389/fonc.2022.812560. North America (athymic mice)
944. Rango et al. (2022). Biomedicines. 2022 Mar 12;10(3):659. doi: 10.3390/biomedicines10030659. Italy (athymic mice)
945. Nilsen et al. (2022). Mol Oncol. 2022 Mar;16(6):1402-1419. doi: 10.1002/1878-0261. Norway (athymic mice)
946. Espinoza et al. (2022). Am J Cancer Res. 2022 Feb 15;12(2):839-851. North America (athymic mice)
947. Te Boekhorst et al. (2022). Curr Biol. 2022 Jan 24;32(2):412-427.e8. doi: 10.1016/j.cub.2021.11.040. Netherlands (athymic mice)
948. Choi et al. (2022). Cell Rep. 2022 Jan 18;38(3):110278. doi: 10.1016/j.celrep.2021.110278. North America (athymic mice)
949. Kuravi et al. (2022). NPJ Precis Oncol. 2022 Jan 18;6(1):3. doi: 10.1038/s41698-021-00246-4. North America (athymic mice)
950. Yu et al. (2022). Cancers (Basel). 2022 Jan 7;14(2):278. doi: 10.3390/cancers14020278. Finland (athymic mice)
951. Parida et al. (2022). Cell Metab. 2022 Jan 4;34(1):90-105.e7. doi: 10.1016/j.cmet.2021.12.001. North America (athymic mice)
952. Al-Jamal et al. (2022). Nanotheranostics. 2022 Jan 1;6(3):230-242. doi: 10.7150/ntno.61280. UK (athymic mice)
953. Zalles et al. (2022). J Cell Mol Med. 2022 Jan;26(2):570-582. doi: 10.1111/jcmm.17133. North America (athymic mice)
954. Lupia et al. (2022). Int J Cancer. 2022 Jul 15;151(2):240-254. doi: 10.1002/ijc.33983. Italy (athymic mice)
955. Ciccone et al. (2022). Int J Mol Med. 2022 Jul;50(1):99. doi: 10.3892/ijmm.2022.5155. Italy (athymic mice)
956. Lecointre et al. (2022). Cancers (Basel). 2022 Jun 16;14(12):2981. doi: 10.3390/cancers14122981. France (athymic mice)
957. Guendisch et al. (2022). Front Cell Dev Biol. 2022 May 26;10:916033. doi: 10.3389/fcell.2022.916033. Switzerland (athymic mice)
958. Yadav et al. (2022). Cancer Res. 2022 May 16;82(10):1872-1889. doi: 10.1158/0008-5472.CAN-21-2106. North America (athymic mice)
959. Yange et al. (2022). Am J Cancer Res. 2022 May 15;12(5):2173-2188. North America (athymic mice)
960. Di Maira et al. (2022). J Pathol. 2022 May;257(1):82-95. doi: 10.1002/path.5871. Italy (athymic mice)
961. Shimura et al. (2022). Br J Cancer. 2022 Feb;126(2):228-237. doi: 10.1038/s41416-021-01581-w. North America (athymic mice)
962. Zhao et al. (2022). Pharmaceuticals (Basel). 2022 Feb 22;15(3):262. doi: 10.3390/ph15030262. North America (BALB/C nude mice)
963. Dunn et al. (2022). Oncogene. 2022 Nov;41(46):5046-5060. doi: 10.1038/s41388-022-02482-9. UK (athymic mice)
964. Seok et al. (2023). Non-coding RNA Research. 2023. Volume 8, Issue 2 doi: org/10.1016/j.ncrna.2022.12.005. Korea (BALB/C nude mice)
965. Filippone et al. (2022). Cancers (Basel). 2022 Dec 29;15(1):217. doi: 10.3390/cancers15010217. Italy (BALB/C nude mice)
966. Losada et al. (2022). Journal of Endocrinology. 2022. JOE-22-0229. doi: 10.1530/JOE-22-0229. UK (BALB/C nude mice)
967. Avena et al. (2022). Cancers (Basel). 2022 Mar 16;14(6):1521. doi: 10.3390/cancers14061521. North America (SCID)
968. Kanakkanthara et al. (2022). Cancer Res. 2022 Jan 15;82(2):307-319. doi: 10.1158/0008-5472.CAN-21-0732. North America (SCID-beige mice)
969. Tonon et al. (2022). Cancers (Basel). 2022 Mar 23;14(7):1630. doi: 10.3390/cancers14071630. Italy (SCID)
970. Kapur et al. (2022). Cancers (Basel). 2022 May 5;14(9):2297. doi: 10.3390/cancers14092297. North America (C57BL/6)
971. Pozzi et al. (2022). JCI Insight. 2022 Sep 8;7(17):e154804. doi: 10.1172/jci.insight.154804. Israel (C57BL/6)
972. Dragojevic et al. (2022). Molecules. 2022 May 24;27(11):3371. doi: 10.3390/molecules27113371. North America (athymic mice)
973. Galisova et al. (2022). ACS Nano 2022, 16, 8, 12276–12289. doi: 10.1021/acsnano.2c03119 Israel (athymic mice)
974. Hao et al. (2022). Mol Biomed. 2022 Aug 17;3(1):26. doi: 10.1186/s43556-022-00086-z. Netherlands (C57BL/6)
975. Hamdan et al. (2023). Molecular Therapy: Oncolytics (2023), doi: 10.1016/j.omto.2023.01.006. Finland (C57BL/6)
976. Singh et al. (2022). PLoS Biol. 2022 May 26;20(5):e3001624. doi: 10.1371/journal.pbio.3001624. North America (CB.17.SCID)
977. Silveira Rabelo et al. (2022). Molecules. 2022 Oct 25;27(21):7245. doi: 10.3390/molecules27217245. North America (BALB/C)
978. Kim et al. (2022). Life (Basel). 2022 Feb 17;12(2):303. doi: 10.3390/life12020303. Korea (BALB/C nude)
979. Martinez-Turtos et al. (2022). Oncoimmunology. 2022 Aug 27;11(1):2116844. doi: 10.1080/2162402X.2022.2116844. France (C57BL/6)
980. Sasaki et al. (2022). J Neurosurg. 2022 Nov 11;1-10. doi: 10.3171/2022.9.JNS22715. North America (BALB/C nude)
981. Sancho-Albero et al. (2022). J Extracell Vesicles. 2022 Mar;11(3):e12193. doi: 10.1002/jev2.12193. Spain (BALB/C nude)
982. Chakraborty et al. (2022). Mol Cancer Ther. 2022 Oct 7;21(10):1535-1546. doi: 10.1158/1535-7163.MCT-22-0241. UK (athymic mice)
983. Liu et al. (2022). Cancers (Basel). 2022 Aug 30;14(17):4208. doi: 10.3390/cancers14174208. North America (Balb/c)
984. Martella et al. (2022). Pharmaceutics. 2022 Mar 19;14(3):677. doi: 10.3390/pharmaceutics14030677. Italy (Balb/c nude)
985. Azmanova et al. (2022). Chembiochem. 2022 Sep 16;23(18):e202200259. doi: 10.1002/cbic.202200259. UK (Balb/c nude)
986. Basilotta et al. (2023). International Journal of Molecular Sciences. 2023 Feb 1;24(3):2777. Italy (Balb/c nude)
987. Chan et al. (2022). Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3668-3678. doi: 10.1007/s00259-022-05835-4.

Many factors can influence your selection of an appropriate research model. These published studies are identified to assist you in your selection. Inotiv does not guarantee model performance in research studies.

The cell line abbreviation “(PDX)” is utilized as a generic naming convention of a “Patient-derived Xenograft” in absence of a formal name by the researcher(s).

 

Learn more

INSIGHTS, Keep up-to-date with the latest industry thinking and scientific insights

SCIENTIFIC INSIGHTS

Keep up-to-date with the latest industry thinking and scientific insights

Explore today Explore today  
 ,  

More than 90 years of working together, to build a healthier and safer world  

 

Explore our history Explore our history  

Subscribe to updates from Inotiv

Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.

Subscribe now